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Figure 4. NAT activity of recombinant hNaa10p WT or p.Ser37Pro 
towards synthetic N-terminal peptides. A) and B) Purified MBP-hNaa10p 
WT or p.Ser37Pro were mixed with the indicated oligopeptide substrates (200 
µM for SESSS and 250 µM for DDDIA) and saturated levels of acetyl-CoA 
(400 µM). Aliquots were collected at indicated time points and the acetylation 
reactions were quantified using reverse phase HPLC peptide separation. 
Error bars indicate the standard deviation based on three independent 
experiments. The five first amino acids in the peptides are indicated, for 
further details see materials and methods. Time dependent acetylation 
reactions were performed to determine initial velocity conditions when 
comparing the WT and Ser37Pro NAT-activities towards different 
oligopeptides. C) Purified MBP-hNaa10p WT or p.Ser37Pro were mixed with 
the indicated oligopeptide substrates (200 µM for SESSS and AVFAD, and 
250 µM for DDDIA and EEEIA) and saturated levels of acetyl-CoA (400 µM) 
and incubated for 15 minutes (DDDIA and EEEIA) or 20 minutes (SESSS and 
AVFAD), at 37°C in acetylation buffer. The acetylation activity was determined 
as above. Error bars indicate the standard deviation based on three 
independent experiments. Black bars indicate the acetylation capacity of the 
MBP-hNaa10p wild type (WT), while white bars indicate the acetylation 
capacity of the MBP-hNaa10p mutant p.Ser37Pro. The five first amino acids 
in the peptides are indicated. 
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  ObjecRves	  
•  The	  parRcipants	  will	  be	  able	  to	  discuss	  the	  
extraordinary	  amount	  of	  variable	  expressivity	  
seen	  in	  neurodevelopmental	  	  disorders.	  
•  The	  parRcipants	  will	  plan	  ways	  in	  which	  to	  
integrate	  genomic	  and	  phenotypic	  
longitudinal	  data	  to	  prevent	  the	  development	  
of	  certain	  illnesses.	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Advisory	  Boards	  
“Using	  a	  patented	  process	  invented	  by	  Dr.	  Lee	  Silver	  of	  Princeton	  University,	  we	  predict	  
what	  would	  happen	  if	  the	  genes	  of	  two	  biological	  parents	  were	  to	  come	  together—well	  
before	  there's	  a	  pregnancy.	  This	  technology	  allows	  us	  to	  analyze	  thousands	  of	  potenRal	  
geneRc	  combinaRons	  for	  millions	  of	  mutaRons	  that	  could	  aﬀect	  the	  health	  of	  your	  
future	  family”.	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The	  Story	  began	  for	  me	  at	  least	  by	  1993….	  
	  
when	  I	  joined	  the	  lab	  of	  Don	  St.Germain	  to	  study	  
the	  role	  of	  thyroid	  hormone	  in	  cre*nism,	  which	  is	  
caused	  by	  lack	  of	  iodine	  during	  maternal	  
pregnancy,	  so	  this	  is	  an	  environmentally	  triggered	  
disease.	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‘‘In reality, discoveries are due to people at the edge of the
formalised groups of researchers’’
Pierre Laszlo
Fifty years ago, I was the co-author1 of the first paper that
showed the presence of an additional chromosome (Lejeune
et al. 1959) in the syndrome identified by Langdon Down
in 1866 and commonly known as ‘‘mongolism’’ in France at
the time. This, the first autosomal chromosome aberration
recognised in the cells of the human species, was named
trisomy 21. I thought it would be of historical interest to bring
my own personal testimony as an actor in that discovery.
A historical background
Going back to 1958 involves rediscovering the context and
the firmly held beliefs of that period. Although it had been
accepted for decades that human beings possessed 48 chro-
mosomes, Tjio and Levan (1956) demonstrated in 1956 that
there were in fact only 46. This did not affect many people,
apart from a few geneticists, and for a long time 48 was still
the figure taught in schools. This stage, which seemed sim-
ple, was followed by other more important stages that
brought us closer to finding the origins of life; however, this
did not create such a stir in the media as the launch of the first
artificial satellite Sputnik (meaning ‘‘fellow traveller’’ in
Russian) a few months later, which drew us closer to finding
the origins of the universe. Science advances on different
levels, depending on the disciplines.
It had been necessary to wait 30 years before the genetic
laws of peas, as observed by Johan Mendel or ‘Brother
Gregor’ of the Augustinian Monastery of Brno, was recog-
nised by biologists. Soon after this, Nettie Stevens revealed
the existence of sex chromosomes in a certain species of
beetle (Gilgenkrantz 2008). In about 1910, Morgan’s work
on Drosophila, the providential fruit fly with its amazingly
fast reproduction rate and giant chromosomes, laid the first
foundations of cytogenetics (Morgan et al. 1925). Had it not
been for the attitudes of Alexis Carrel (1912 Nobel Prize
winner) during the Occupation (Gilgenkrantz and Rivera
2003), his cell culture experiments would have been widely
used. However, a long sequence of errors and failures dis-
couraged the researchers. And it was not until 1949, and then
only on cat neuronal cells, that Barr and Bertram (1949)
discovered the existence of a body only in the female
nucleus; this in fact proved to be a general phenomenon that
indicated the presence of two X-chromosomes. The cyto-
logical explanation for this (lyonisation) fell to Lyon (1961).
Simple swabs of the mucous membrane in the mouth then
allowed inter-sexual states to be diagnosed.
This article by Marthe Gautier was translated from the French by
Cardiff University Centre for Lifelong Learning and Peter S. Harper.
The commentary is by Peter Harper. Originally published in
Me´decine Sciences [Gautier M (2009) Cinquantenaire de la trisomie
21. Retour sur une de´couverte. Med Sci (Paris) 25(3): 311–315], this
article now reappears in English by kind permission of the publisher,
E´ditions EDK.
M. Gautier
6 Rue de Douai, 75009 Paris, France
e-mail: marthe.gautier@free.fr
P. S. Harper (&)
Institute of Medical Genetics, School of Medicine,
Cardiff University, Heath Park, Cardiff CF14 4XN, UK
e-mail: HarperPS@cardiff.ac.uk
1 By a slip of the pen that I dare not interpret, my name was wrongly
entered as ‘‘Marie Gauthier’’. The error was corrected in subsequent
publications.
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It would have been a personal triumph for 
Marthe Gautier, an 88-ye r-old pediatric 
cardiologist and scientist living in Paris. On 
31 January, during  meeting in Bordeaux, 
Gautier was to r ceive a medal for her role in 
the discovery of the cause of Down syndrome 
in the late 1950s. In a speech, she planned to 
tell an audience of younger Fr ch ge eticists 
her story about the discovery—and how she 
felt the credit she deserv d went to a ale col-
league, Jérôme Lejeune. 
But Gautier’s talk was canceled just hours 
in advance, and she received the medal a d y 
later in a small, private ceremony. The French 
Federation of Human Genetics (FFGH), 
which organized the meeting, decided to 
scrap the event after two bailiffs showed up 
with a court order granting them permission 
to tape Gautier’s speech. They were sent by the 
Jérôme Lejeune Foundation, which wanted 
to have a record of the talk. The foundation, 
which supp rts research and car  for patients 
with genetic intellectual disabilities and 
campaigns against abortion, said it had 
reason to believe Gautier would “tarnish” the 
memory of Lejeune, who died in 1994.
A brilliant cytogeneticist with a storied 
career, Lejeune has become widely known 
as the scientist who discovered that Down 
syndrome is caused by an extra copy of 
chromosome 21. H  receiv d many awards, 
including one from former U.S. President John 
F. Kennedy. But in recent years, Gautier has 
claimed that she did most of the experimental 
work for the discov ry. In the French 
newspaper Le Monde, Alain Bernheim, the 
pre ident of the French Society of Human 
Genetics, last week compared her ca e to that 
of Rosalind Franklin, whose contribution to 
the discovery of the double helix structure of 
DNA i  the early 1950s was long overlooked.
In an e-mail to Science, 
Gautier referred to an 
interview published on the 
Web for her version of events 
more than half a century ago. 
In it, she explained that she 
worked on Down syndrome 
in the pediatric unit led 
by Raymond Turpin at the 
Armand-Trousseau Hospital 
in Paris, which she joined in 
1956 after a year at Harvard 
Medical School in Boston. 
Hum n cytogenetics was 
just coming of age. In 1956, a Swedish team 
showed that humans have 46 chromosomes in 
every cell, not 48, as was widely beli ved. In 
the United States, Gautier had learned to grow 
heart cell cultures, so she proposed to set up 
an advanced cell culture lab and study Down 
syndrome. She says she received her first 
patient sample in May 1958; examing slides, 
she soon not ced an extra chromosome, but 
she was unable to identify it or take pictures 
with her low-power microscope. In June 1958, 
she “naively” accepted an offer from Lejeune, 
who Gautier says was studying Down 
syndrome using other techniques, to take her 
slides and get them photographed. 
Gautier claims she was “shocked” 
when, after more than 6 months of silence, 
she learned that the discovery was about to 
be published in the journal of the French 
Academy of Sciences, with Lejeune as the 
fi rst author and Turpin the last; Gautier was 
in the middle, her last name misspelled 
as Gauthier. Gautier doesn’t dispute that 
Lejeune identifi ed the 47th chromosome as 
an extra copy of chromosome 21, but she 
maintains that she was the fi rst to notice the 
abnormal count.
While ackowledging that Gautier played a 
role, the Jérôme Lejeune Foundation claims 
that Lejeune himself made the discovery. “In 
July 1958, during a study of chromosomes 
of a so-called ‘mongoloid’ child, [Lejeune] 
discovered the existence of an extra 
chromosome on the 21st pair,” according to 
the foundation’s website. The foundation has 
denied that Lejeune appropriated Gautier’s 
discovery; in a press statement, it says a letter 
Turpin sent in October 1958 suggests Gautier 
still hadn’t seen the 47 chromosomes.  
Things came to a head at the meeting in 
Bordeaux. After calling off Gautier’s talk and 
the award ceremony, FFGH issued a statement 
saying it would have been “unacceptable” to 
hold the ceremony under the threat of a legal 
suit. But the federation also 
said it “bitterly regretted” the 
cancellation and condemned 
the use of legal power to 
put pressure on a scientifi c 
meeting. 
Simone Gilgenkrantz, a 
professor emeritus of human 
genetics at the University 
of Lorraine in France and 
a friend of Gautier’s, says 
the presentation, which she 
has seen, was “completely 
innocuous.” Gautier writes 
in an e-mail to Science that she accepted the 
decision and that she felt unprepared to deal 
with what she calls “an aggression.” “To talk 
under the pressure of justice is not tolerable 
for me or anyone else,” she writes.
Ideology is fueling some of the rancor. 
Lejeune, a staunch Catholic, was horrified 
by the advent of prenatal diagnostics, which 
made it possible to screen fetuses for Down 
syndrome and other abnormalities, and 
abort those afflicted. He set out to find a 
After More Than 50 Years, a Dispute 
Ov r Down Sy drome Discov ry
H I STO RY  O F  S C I E N C E
14 FEBRUARY 2014    VOL 343    SCIENCE    www.sciencemag.org  
Claiming credit. Marthe Gautier’s talk at a recent 
genetics meeting in Bordeaux was canceled.
First author. Jérôme Lejeune, who 
passed away in 1994.
Published by AAAS
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It would have been a personal triumph for 
Marthe Gautier, an 88-year-old pediatric 
cardiologist and scientist living in Paris. On 
31 January, during a meeting in Bordeaux, 
Gautier was to receive a medal for her role in 
the discovery of the cause of Down syndrome 
in the late 1950s. In a speech, she planned to 
tell an audience of younger French geneticists 
her story about the discovery—and how she 
felt the credit she deserved went to a male col-
league, Jérôme Lejeune. 
But Gautier’s talk was canceled just hours 
in advance, and she received the medal a day 
later in a small, private ceremony. The French 
Federation of Human Gene ics (FFGH), 
which organized the meeting, decided to 
scrap th  event after two bailiffs showed up 
with a court order granting them permission 
to tape G utier’s speech. They were sent by the 
Jérôme Lejeune Foun ation, w ich wanted 
to have a record of the talk. The foundation, 
which supports research and care for patients 
with genetic intellectual disabilities and 
campaigns against abortion, said it had 
reason to believe Gautier would “tarnish” the 
memory of Lejeune, who died in 1994.
A brilliant cytogeneticist with a storie  
career, Lejeune has become widely known 
as the scientist who discovered that Down 
syndrome is caused by an extra copy of 
chromoso e 21. He received many awards, 
including one from former U.S. President John 
F. Kennedy. But in recent years, Gautier has 
claimed that she did most of the experimental 
work for the discovery. In the French 
newspaper Le Monde, Alain Bernheim, the 
president of the French Society of Human 
Genetics, last week compared her case to that 
of Rosalind Franklin, whose contribution to 
the discovery of the double helix structure of 
DNA in the early 1950s was long overlooked.
In an e-mail to Science, 
Gautier referred to an 
interview published on the 
Web for her version of events 
more than half a century ago. 
In it, she explained that she 
worked on Down syndrome 
in the pediatric unit led 
by Raymond Turpin at the 
Armand-Trousseau Hospital 
in Paris, whic  she joined in 
1956 after a year at Harvard 
Medical School in Boston. 
Human cytogenetics was 
just coming of age. In 1956, a Swedish team 
showed that humans have 46 chro osomes in 
every cell, not 48, as was widely believed. In 
the United States, Gautier had learned to grow 
heart cell cultures, so she proposed to set up 
an advanced cell culture lab and study Down 
syndrome. She says she received her first 
patient sample in May 1958; examing slide , 
she soon noticed an ext a chromosome, but 
she was unable to identify it or take pictures 
with her low-power microscope. In June 1958, 
she “naively” accepted an offer from Lejeune, 
who Gautier says was studying Down 
syndrome using other techniques, to take her 
slides and get them photographed. 
Gautier claims she was “shocked” 
when, after more than 6 months of silence, 
she learned that the discovery was about to 
be published in the journal of the French 
Academy of Sciences, with Lejeune as the 
fi rst author and Turpin the last; Gautier was 
in the middle, her last name misspelled 
as Gauthier. Gautier doesn’t dispute that 
Lejeune identifi ed the 47th chromosome as 
an extra copy of chromosome 21, but she 
maintains that she was the fi rst to notice the 
abnormal count.
While ackowledging that Gautier played a 
role, the Jérôme Lejeune Foundation claims 
that Lejeune himself made the discovery. “In 
July 1958, during a study of chromosomes 
of a so-called ‘mongoloid’ child, [Lejeune] 
discovered the existence of an extra 
chromosome on the 21st pair,” according to 
the foundation’s website. The foundation has 
denied that Lejeune appropriated Gautier’s 
discovery; in a press statement, it says a letter 
Turpin sent in October 1958 suggests Gautier 
still hadn’t seen the 47 chromosomes.  
Things came to a head at the meeting in 
Bordeaux. After calling off Gautier’s talk and 
the award ceremony, FFGH issued a statement 
saying it would have been “unacceptable” to 
hold the ceremony under the threat of a legal 
suit. But the federation also 
said it “bitterly regretted” the 
cancellation and condemned 
the use of legal ower to 
put pressure on a scientifi c 
meeting. 
Simone Gilgenkrantz, a 
professor emeritus of human 
genetics at the University 
of Lorraine in France and 
a friend of Gautier’s, says 
the presentation, which she 
has seen, was “completely 
innocuous.” Gautier writes 
in an e-mail to Science that she accepted the 
decision and that she felt unprepared to deal 
with what she calls “an aggression.” “To talk 
under the pressure of justice is not tolerable 
for me or anyone else,” she writes.
Ideology is fueling some of the rancor. 
Lejeune, a staunch Catholic, was horrified 
by the advent of prenatal diagnostics, which 
made it possible to screen fetuses for Down 
syndrome and other abnormalities, and 
abort those afflicted. He set out to find a 
After More Than 50 Years, a Dispute 
Over Down Syndrome Discovery
H I STO RY  O F  S C I E N C E
14 FEBRUARY 2014    VOL 343    SCIENCE    www.sciencemag.org  
Claiming credit. Marthe Gautier’s talk at a recent 
genetics meeting in Bordeaux was canceled.
First auth r. Jérôme Lejeune, who 
passed away in 1994.
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Velocardiofacial	  (22q11.2)	  Syndrome	  
16p11.2	  deleRon,	  not	  in	  mother	  or	  
father,	  only	  in	  child.	  	  
5	  years	  old,	  but	  
developmental	  age	  of	  2	  year	  
old.	  
Speaks	  a	  few	  words,	  almost	  
unintelligible.	  
Very	  hyperacRve.	  
Can	  be	  withdrawn	  and	  has	  at	  
Rmes	  been	  diagnosed	  with	  
“auRsm”.	  
*Private	  Photograph	  –	  Do	  not	  further	  distribute.	  
16p11.2 deletion 
Fernandez B A et al. J Med Genet 2010;47:195-203 
©2010 by BMJ Publishing Group Ltd 
Clinical photographs. (a and b) Proband 2 (de novo deletion 16p11.2). Note long 
narrow palpebral fissures, short delicate nose, short neck and brachydactyly with 
2–3 cutaneous toe syndactyly. (c and d) Mother of proband 3 (both with 
deletions). Note her large ears, smooth philtrum and short fifth toes. 	  
Discovering	  a	  new	  syndrome	  and	  its	  
geneRc	  basis.	  
"This	  exempliﬁes	  an	  excepRonally	  
rare	  disease,	  but	  the	  same	  type	  
of	  strategy	  is	  now	  going	  to	  be	  
applied	  to	  more	  common	  
diseases	  to	  get	  the	  root	  cause,"	  
says	  Eric	  Topol,	  a	  medical	  
geneRcist	  at	  the	  Scripps	  Research	  
InsRtute	  in	  La	  Jolla,	  California.	  
	  
"This	  is	  one	  of	  the	  most	  exciRng	  
things	  in	  medicine,"	  says	  Topol.	  
"We're	  going	  to	  take	  the	  term	  
'idiopathic'	  which,	  basically	  
means	  'we	  don't'	  know,'	  and	  
eliminate	  it."	  
Ogden	  Syndrome	  
We	  found	  the	  SAME	  mutaRon	  in	  two	  unrelated	  families,	  with	  a	  very	  similar	  
phenotype	  in	  both	  families,	  helping	  prove	  that	  this	  genotype	  contributes	  to	  the	  
phenotype	  observed.	  
First	  boy.	  Called	  “a	  liQle	  old	  man”	  by	  
the	  family.	  Died	  around	  ~1	  year	  of	  
age,	  from	  cardiac	  arrhythmias.	  
This	  is	  the	  ﬁrst	  boy	  in	  the	  late	  1970’s.	  
prominence	  of	  eyes,	  down-­‐sloping	  palpebral	  ﬁssures,	  thickened	  
eyelids,	  large	  ears,	  beaking	  of	  nose,	  ﬂared	  nares,	  hypoplasRc	  nasal	  
alae,	  short	  columella,	  protruding	  upper	  lip,	  micro-­‐retrognathia	  
	  
This	  is	  the	  “Proband”	  photograph	  presented	  at	  Case	  Conference.	  
II-1 III-2 
A	  
B	  
C	   D	  
II-­‐1	   II-­‐6	   III-­‐7	  III-­‐4	   III-­‐6	  
These	  are	  the	  Major	  Features	  of	  the	  Syndrome.	  
u  We	  performed	  X-­‐chromosome	  exon	  capture	  
with	  Agilent,	  followed	  by	  Next	  Gen	  
Sequencing	  with	  Illumina.	  
u  We	  analyzed	  the	  data	  with	  ANNOVAR	  and	  
VAAST	  (Variant	  Annota*on,	  Analysis	  and	  
Search	  Tool).	  New	  computa*onal	  tools	  for	  
iden*fying	  disease-­‐causing	  muta*ons	  by	  
individual	  genome	  sequencing.	  	  
	  
Yandell,	  M.	  et	  al.	  2011.	  “A	  probabilisRc	  disease-­‐gene	  ﬁnder	  for	  personal	  
genomes.”	  Genome	  Res.	  21	  (2011).	  doi:10.1101/gr.123158.111.	  	  	  
	  
Wang,	  K.,	  Li,	  M.,	  and	  Hakonarson,	  H.	  (2010).	  ANNOVAR:	  funcRonal	  annotaRon	  
of	  geneRc	  variants	  from	  high-­‐throughput	  sequencing	  data.	  Nucleic	  Acids	  Res	  
38,	  e164.	  
	  	  
	  
	  
VAAST	  integrates	  AAS	  &	  Variant	  frequencies	  
in	  a	  single	  probabilis*c	  framework	  	  
 
•   non-coding variants scored using allele frequency differences 
•  ni : frequency of variant type among all variants observed in 
Background and Target genomes 
 
•  ai: frequency of variant type among disease causing mutations in 
OMIM 
•  This approach means that every variant can be scored, non-synonymous,   
  synonymous, coding, and non-coding. Phylogenetic conservation not     
  required. 

Mutation 
WT 
C C C 
Pro37 
Proband  
Unaffected 
Brother 
C T T G G	  T C T C 
Ser37 
C 
T 
This is the mutation we found… one nucleotide change 
out of 6 billion nucleotides in a diploid genome… 
IdenRty	  by	  Descent	  Analysis	  shows	  
that	  the	  mutaRon	  must	  have	  arisen	  
independently	  in	  two	  diﬀerent	  
families.	  
Courtesy	  of	  Chad	  Huﬀ	  and	  Lynn	  Jorde	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random mutation modeling40 to calculate the likelihood that observed 
(de novo) mutations have a damaging effect. Similar prioritizations 
are provided by tools that score individual mutation severity (SIFT, 
PolyPhen2, MutationTaster, MutPred, CONDEL, etc.), some of which 
can be adapted to a gene-based prioritization score from genome-wide 
data41. These population data provide a powerful unbiased approach 
to home in on genes that are likely to be among the most penetrant 
because of the complete absence of disruptive variation in the general 
population (for example, CHD8 or DYRK1A). A critical aspect of such 
analyses is the reliability of a particular gene model. Most human 
genes show evidence of alternative splice forms, many of which have 
no known function. Apparent hotspots of mutation for a particular 
exon (often exon-intron boundaries) in both cases and controls may 
suggest misannotation, the presence of a processed pseudogene or an 
alternative, nonfunctional splice form.
Pathway enrichment and links to cancer biology
Another popular approach to discern the most important gene 
candidates for further disease association and characterization has 
been to identify specific biological networks of genes enriched in 
cases as compared to controls. Although this approach cannot be used 
unequivocally to define causality, membership of a specific gene in a 
particular protein-protein interaction (PPI) or coexpression network 
may increase the likelihood of its association with disease. Numerous 
studies have reported significant enrichment of both de novo 
CNV and single-nucleotide variant (SNV) mutations in particular 
pathways3,4,42,43. O’Roak et al.3, for example, reported a significant 
enrichment of de novo disruptive autism mutations among proteins 
associated with chromatin remodeling and ?-catenin and WNT 
signaling—a finding that was replicated in a follow-up resequencing 
study of more than 2,400 probands. One recent instance, in which 
membership of a new candidate gene in a PPI network led to the 
discovery of an autism-associated gene, is ADNP. A single ADNP 
LoF mutation was initially observed in exome sequencing studies. 
Although the observed mutation frequency in this gene did not reach 
statistical significance when cases and controls were compared20, 
it was strongly implicated in the PPI network originally defined 
by O’Roak et al.3 Targeted resequencing experiments combined 
with clinical exome sequencing identified several more cases with 
de novo mutations and remarkably similar phenotypes represent-
ing a new SWI-SNF–related autism syndrome (Fig. 3)44. Notably, 
many of the genes implicated in the ?-catenin pathway have also been 
described as mutated in patients with ID1 but not in patients with 
SCZ. Similarly, an enrichment of genes interacting with FMR1 (also 
known as FMRP)—the gene responsible for fragile X syndrome—has 
been reported with de novo mutations in ASD5, epilepsy11 and, most 
recently, SCZ10,45. Whether this observation is due to the relative high 
incidence of cases that also presented with comorbid ID remains to 
be determined.
In addition to PPI networks, studies of coexpression have shown 
enrichment for specific spatio-temporal patterns of expression. 
A study of coexpressed genes affected by de novo mutations reported 
an enrichment in fetal prefrontal cortical network in SCZ8, which is 
in line with the finding by Xu et al.9 that genes with higher expression 
Table 4 Recurrent identical de novo mutations in 6 genes identified in 11 exome studies with different neurodevelopmental phenotypes
Gene Coding effect Mutation (genomic DNA level) Mutation (cDNA level)
Mutation  
(protein level) Study Disorder
ALG13 Missense ChrX(GRCh37):g.110928268A>G NM_001099922.2:c.320A>G p.Asn107Ser de Ligt et al.1 ID
ALG13 Missense ChrX(GRCh37):g.110928268A>G NM_001099922.2:c.320A>G p.Asn107Ser Allen et al.11 EE
ALG13 Missense ChrX(GRCh37):g.110928268A>G NM_001099922.2:c.320A>G p.Asn107Ser Allen et al.11 EE
KCNQ3 Missense Chr8(GRCh37):g.133192493G>A NM_001204824.1:c.328C>T p.Arg110Cys Rauch et al.2 ID
KCNQ3 Missense Chr8(GRCh37):g.133192493G>A NM_001204824.1:c.328C>T p.Arg110Cys Allen et al.11 EE
SCN1A Splice donor LRG_8:g.24003G>A NM_006920.4:c.602+1G>A p.? Allen et al.11 EE
SCN1A Splice donor LRG_8:g.24003G>A NM_006920.4:c.602+1G>A p.? Allen et al.11 EE
CUX2 Missense Chr12(GRCh37):g.111748354G>A NM_015267.3:c.1768G>A p.Glu590Lys Rauch et al.2 ID
CUX2 Missense Chr12(GRCh37):g.111748354G>A NM_015267.3:c.1768G>A p.Glu590Lys Allen et al.11 EE
SCN2A Missense Chr2(GRCh37):g.166198975G>A NM_021007.2:c.2558G>A p.Arg853Gln Allen et al.11 EE
SCN2A Missense Chr2(GRCh37):g.166198975G>A NM_021007.2:c.2558G>A p.Arg853Gln Allen et al.11 EE
DUSP15 Missense Chr20(GRCh37):g.30450489G>A NM_080611.2:c.320C>T p.Thr107Met Neale et al.7 ASD
DUSP15 Missense Chr20(GRCh37):g.30450489G>A NM_080611.2:c.320C>T p.Thr107Met Fromer et al.10 SCZ
EE, epileptic encephalopathies; ASD, autism spectrum disorder; ID, intellectual disability; SCZ, schizophrenia.
Figure 1 Genes with recurrent de novo mutations in four 
neurodevelopmental disorders. (a) We estimate the number of fully penetrant 
genes that can explain disease once mutated, based on a de novo model 
using the ‘unseen species problem’. We consider all recurrent missense or 
LoF de novo mutations pathogenic, as well as a defined fraction of mutations 
in genes observed just once (because it is unlikely that all de novo mutations 
are pathogenic). The ratio between genes mutated recurrently and the rate 
of singleton mutations suggests an estimate for the true number of genes 
pathogenic when mutated. Including more singleton mutations increases 
the fraction of each disorder explained by single de novo SNVs at the cost 
of including more genes as pathogenic. Initial exome sequencing studies of 
epilepsy and ID focused on specific pediatric subtypes or the most severe 
cases; thus, the number of generalized epilepsy- or ID-associated genes is 
likely to be much higher. EE, epileptic encephalopathies; ASD, autism spectrum disorder; ID, intellectual disability; SCZ, schizophrenia. (b) Expected  
hit rate (or sensitivity) of true positive genes discovered using trio sequencing studies (under a family-wise error rate of 5%; that is, each gene passes exome-
wide significance of 2.6 × 10−6). We estimate the power of trio sequencing to detect statistically significant associations for disease-associated genes,  
under the assumption that 10% or 20% of singleton mutations could be fully penetrant (vertical bars in a). We assume the distribution of these genes is 
uniform within each disorder and that they do not differ significantly from all genes in terms of length and mutability, although these are taken into account 
when determining significance.
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Recent exome (and genome) sequencing studies of families have aimed 
to comprehensively discover genetic variation to identify the most 
likely causal mutation in patients with disease. Sequencing studies of 
parent-proband trios for probands with intellectual disability (ID)1,2, 
autism spectrum disorder (ASD)3–7, schizophrenia (SCZ)8–10 and epi-
lepsy11 have all suggested that de novo point mutations are important 
in pediatric and adult disorders of brain development (Table 1). The 
relative contribution of de novo mutations to each disorder remains to 
be determined but appears to correlate well with the degree of reduced 
fitness or fecundity of the given condition12. However, not only 
de novo events but also rare inherited copy number variants (CNVs) 
can have an effect on fecundity, though their overall effect on fecundity 
is still debated13. Biologically, 75–80% of de novo point mutations arise 
paternally3,14, likely as a result of the greater number of cell divisions 
in the male germline lineage than in the female lineage. These findings 
are consistent with some epidemiological data that find advancing 
paternal age to be a significant predictor of ASD, ID and SCZ15–17 and 
argue for the need to properly control for paternal age when comparing 
mutation rates between probands and siblings. The importance of 
de novo and private rare mutations is especially important clinically, 
as there are now reports of diagnostic yields ranging from 10–55%  
for select (usually the most severe) groups of patients with ID1,2 and 
epilepsy18, in addition to resolution of unsolved Mendelian disorders19. 
It is clear that next-generation sequencing approaches have provided 
powerful tools for identifying genes harboring potentially pathogenic 
mutations. Deciding which genes to pursue, however, is not always 
self-evident because follow-up research and diagnostic studies are 
critical to understanding the full contribution of a particular mutation 
to its respective phenotype.
In this Review, we will discuss the prioritization of candidate genes 
identified through sequencing studies, show emerging trends and 
highlight potential strategies for subsequent functional characteriza-
tion of these neurodevelopmental genes. We focus on lessons learned 
from 11 recent studies that report 2,368 de novo mutations from a 
total of 2,358 probands and 600 de novo mutations from 731 controls 
(Table 1). The bulk of the data originate from sequencing studies 
of parents and probands with ASD, ID and epileptic encephalopa-
thies, but more recent studies have also highlighted the importance of 
de novo mutations in SCZ. There is evidence that de novo mutations, 
particularly disruptive mutations, occur in the same genes despite the 
nosological distinction for these different diseases. For the purpose of 
this Review, we collectively term these diseases ‘neurodevelopmental 
disorders’ but recognize that some, especially adult-onset diseases 
such as SCZ, may have etiologic components that are not neurode-
velopmental in origin.
Recurrently mutated genes
One of the frequently used concepts in considering possible ‘new 
disease genes’ responsible for a given neurodevelopmental pheno-
type is the recurrence of de novo mutations in the same gene, along 
with the absence of such mutations in healthy controls. This rule 
follows the precedent established for the discovery of pathogenic 
de novo CNVs during the last decade, with the highest priority 
given to recurrent mutations that lead to a complete loss of func-
tion of one of the parental copies of the gene. Up to ten independ-
ent reports of de novo mutations in SCN2A and nine independent 
reports of de novo mutations in SCN1A and STXBP1 have been 
described (Tables 2 and 3). Strikingly, de novo mutations in those 
genes have so far been found exclusively in probands and never in 
controls. Simulation data suggest that at least two but certainly three 
or more recurrent de novo loss-of-function (LoF) events (that is, 
predicted nonsense, frameshift or canonical splice site mutations) 
1Department of Human Genetics, Radboud Institute for Medical Life Sciences, 
Radboud University Medical Center, Nijmegen, The Netherlands. 2Department of 
Genome Sciences, University of Washington, Seattle, Washington, USA. 3Howard 
Hughes Medical Institute, University of Washington, Seattle, Washington, USA. 
Correspondence should be addressed to E.E.E. (eee@gs.washington.edu)  
or A.H. (alexander.hoischen@radboudumc.nl).
Received 27 February; accepted 26 March; published online 27 May 2014; 
doi:10.1038/nn.3703
Prioritization of ne rodevelopmental disease 
genes by discovery of new mut tions
Alexande  Hoischen1, Niklas Krumm2 & Evan E Eichler2,3
Advances in genome sequencing technologies have begun to revolutionize neurogenetics, allowing the full spectrum of genetic 
variation to be better understood in relation to disease. Exome sequencing of hundreds to thousands of samples from patients 
with autism spectrum disorder, intellectual disability, epilepsy and schizophrenia provides strong evidence of the importance of 
de novo and gene-disruptive events. There are now several hundred new candidate genes and targeted resequencing technologies 
that allow screening of dozens f genes in tens of thousa ds of individuals with h gh specificity and sensitivity. The de ision 
of which genes to pursue depends on many factors, including recurrence, previous evidence of overlap with pathogenic copy 
number variants, the position of the mutation in the protein, the mutational burden among healthy individuals and membership 
of the candidate gene in disease-implicated protein networks. We discuss these emerging criteria for gene prioritization and the 
potential impact on the field of neuroscience.
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in early fetal life have substantial contribu-
tion to SCZ by de novo mutations. Similarly, 
Willsey et al.46 working with a few high- 
confidence sets of ASD-associated genes as 
seeds reported a convergence of the expres-
sion of these genes in deep-layer cortical 
projection neurons (layers 5 and 6) in mid-
fetal development. Another analysis using a 
larger set of ASD and ID risk genes suggested translational regulation 
by FMR1 and an enrichment in superficial cortical layers43. Implicit 
in these types of analyses is the notion that, while more than 1,000 
genes may be responsible for ASD or ID, in the end the genes will con-
verge on a few highly enriched networks of related genes. It is possible 
that molecular therapies targeted to the network at a specific stage of 
development, as opposed to the individual gene, may be beneficial to 
specific groups of patients.
Related to this, it is intriguing that several recurring genes and 
pathways that have been implicated in neurodevelopmental disease 
have also been associated with different forms of cancer (Fig. 4)47. 
While clear-cut examples such as the mutation of the tumor sup-
pressor genes PTEN (Cowden syndrome) or ARID1B (Coffin-Siris 
syndrome) in neurodevelopmental disease have been extensively 
reviewed48, more recent exome sequencing data from patients with 
neurodevelopmental disease suggest new links. The most striking 
observation here is the identical point mutations reported to cause 
cancer when mutated somatically and severe neurodevelopmental syn-
dromes when mutated in the germline. Examples include the identical 
mutations in SETBP1 (ref. 32), ASXL1 (ref. 49) and EZH2 (ref. 50), as 
well as several genes of the RAS–MAP kinase pathway associated with 
parental-age-effect Mendelian disorders51 (Supplementary Table 1). 
It is important to stress that this is an observation at an individual 
gene level and should not be translated to an epidemiological link: 
that is, this cannot be generalized to speculate that patients with neuro-
developmental disorders in these specific genes will all be at a higher 
risk for certain cancer types. Instead, it is likely that this convergence 
represents a selection of genes that are fundamental to cell biology 
(for example, cell proliferation and/or membership in multi-subunit 
complexes associated with chromatin remodeling). There is also the 
distinct possibility of pleiotropy; that is, the genes and pathways have 
completely unrelated functions, explaining developmental defects and 
cancer independently. Therefore, de novo mutations in those genes 
can result in different outcomes depending on timing, genetic back-
ground and cellular context. Nevertheless, there may be advantages 
to integrating sequence data from patients with neurodevelopmental 
disease and massive sequencing programs devoted to the discovery of 
somatic mutations in tumors—for example, the International Cancer 
Genome Project52. It is possible that these intersections will help to 
further prioritize genes important in both cellular development and 
neurodevelopment.
Phenotypic similarity of recurrent de novo mutations
Although essential, statistical support of recurrent mutations is 
not the sole arbiter in determining pathogenicity of particular 
mutations and genes. In particular, it is important to consider the 
phenotypic presentation and overlap of the individuals with the same 
presumptive underlying genetic lesion. In this regard, we note that 
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Figure 2 CNV and exome intersections define 
candidate genes. (a,b) Deletion (red) and 
duplication (blue) burden for developmental 
delay or ID cases and controls for two genes, 
DYRK1A (a) and MBD5 (b), as compared to 
sporadic LoF mutations on the basis of exome 
sequencing of 209 autism simplex trios. DYRK1A 
is a strong candidate gene for cognitive deficits 
associated with Down syndrome; LoF mutations 
are associated with minibrain phenotype in 
Drosophila65, autism-like behavior in mouse64 
and a deletion syndrome in humans27,63. MBD5 
has been implicated as the causal gene for 
the 2q23.1 deletion syndrome associated with 
epilepsy, autism and ID91,92.
a bFigure 3 Phenotypic similarity of two patients 
with identical PACS1 de novo mutations and two 
patients with similar ADNP mutations. (a) These 
two unrelated patients show identical de novo 
point mutations (c.607C>T; p.Arg203Trp) in 
PACS1 (RefSeq NM_018026.3)53. The striking 
similarity in phenotype includes low anterior 
hairline, highly arched eyebrows, synophrys, 
hypertelorism with downslanted palpebral 
fissures, long eyelashes, a bulbous nasal tip, a 
flat philtrum with a thin upper lip, downturned 
corners of the mouth and low-set ears. Reprinted 
from ref. 53, Copyright (2012), with permission from The American Society of Human Genetics. (b) These two unrelated patients both show LoF mutations 
in ADNP (c.2496_2499delTAAA; p.Asp832Lysfs*80 and c.2157C>G; p.Tyr719*)44 resulting in a new SWI-SNF–related autism syndrome. Patients present 
with clinical similarities, including a prominent forehead, a thin upper lip and a broad nasal bridge. Reprinted from ref. 44.
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A	  conceptual	  model	  of	  genotype-­‐phenotype	  correla*ons.	  	  The	  y	  plane	  represents	  a	  
phenotypic	  spectrum,	  the	  x	  plane	  represents	  the	  canalized	  progression	  of	  development	  
through	  Rme,	  and	  the	  z	  plane	  represents	  environmental	  ﬂuctuaRons.	  	  	  
Time	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Once	  one	  ﬁnds	  a	  validated	  high-­‐eﬀect	  
size	  mutaRon,	  funcRonal	  analysis	  is	  
appropriate.	  
S39 mutation? 
growth defect of 
“humanized” strains 
growth defect at 39°C 
ribosome defect? 
no difference cyclo/doxo? 
 
 
initial 
experiments 
disrupted NatA 
complex 
normal localization 
reduced 
enzymatic 
activity normal nuclear envelope 
X-chromosome skewing in carriers 
Naa10 S37P 
affected in vivo substrates 
S. cerevisiae 
C
. e
le
ga
ns
 
patient cells molecular level 
H
EK
293 cells 
Gene	   Length	   Gene	   Length	   Iden*ty	  Score	  %	  
human	   235	   vs	   c_elegans	   181	   68	  
human	   235	   vs	   s_pombe	   177	   57	  
human	   235	   vs	   s_cerevisiae	   238	   38	  
c_elegans	   181	   vs	   s_pombe	   177	   57	  
c_elegans	   181	   vs	   s_cerevisiae	   238	   48	  
s_pombe	   177	   vs	   s_cerevisiae	   238	   52	  
The	  Scores	  Table	  shows	  the	  pairwise	  scores	  calculated	  for	  every	  pair	  of	  
sequences	  that	  is	  to	  be	  aligned.	  Pairwise	  scores	  are	  simply	  the	  number	  of	  
idenRRes	  between	  the	  two	  sequences,	  divided	  by	  the	  length	  of	  the	  alignment,	  
and	  represented	  as	  a	  percentage.	  This	  alignment	  is	  only	  a	  precursor	  to	  the	  full	  
mulRple	  alignment	  and	  might	  not	  be	  preserved.	  
CLUSTAL 2.1 multiple sequence alignment 
  
h_sapiens_V1      --MNIRNARPEDLMNMQHCNLLCLPENYQMKYYFYHGLSWPQLSYIAE------------ 46 
c_elegans         --MNIRCARVDDLMSMQNANLMCLPENYQMKYYFYHALSWPQLSYIAE------------ 46 
s_pombe           --MDIRPARISDLTGMQNCNLHNLPENYQLKYYLYHAISWPMLSYVAT------------ 46 
s_cerevisiae      MPINIRRATINDIICMQNANLHNLPENYMMKYYMYHILSWPEASFVATTTTLDCEDSDEQ 60 
                    ::** *  .*:  **:.**  ***** :***:** :***  *::*              
  
h_sapiens_V1      DENG--------------------------KIVGYVLAKMEEDPDD---VPHGHITSLAV 77 
c_elegans         DHKG--------------------------NVVGYVLAKMEEDPGE---EPHGHITSLAV 77 
s_pombe           DPKG--------------------------RVVGYVLAKMEEEPKDG--IPHGHITSVSV 78 
s_cerevisiae      DENDKLELTLDGTNDGRTIKLDPTYLAPGEKLVGYVLVKMNDDPDQQNEPPNGHITSLSV 120 
                  * :.                          .:*****.**:::* :    *:*****::* 
  
h_sapiens_V1      KRSHRRLGLAQKLMDQASRAMIENFNAKYVSLHVRKSNRAALHLYSNTLNFQISEVEPKY 137 
c_elegans         KRSYRRLGLANKMMDQTARAMVETYNAKYVSLHVRVSNRAALN-YKNTLKFEIVDTEPKY 136 
s_pombe           MRSYRHLGLAKRLMVQSQRAMVEVYGAKYMSLHVRKSNRAAIHLYRDTLQFDVQGIESKY 138 
s_cerevisiae      MRTYRRMGIAENLMRQALFALREVHQAEYVSLHVRQSNRAALHLYRDTLAFEVLSIEKSY 180 
                   *::*::* :*:.:* *:  *: * . *:*:***** *****:: * :** *::   * .* 
  
h_sapiens_V1      YADGEDAYAMKR--DLTQMADELRRHLELKEKGRHVVLGAIENKVESKGNSPPSSGEACR 195 
c_elegans         YADGEDAYAMRR--DLAKWAEE--RNIEPADR---------------------------- 164 
s_pombe           YADGEDAYAMHK--DFSTLKFD---TPETN------------------------------ 163 
s_cerevisiae      YQDGEDAYAMKKVLKLEELQISNFTHRRLKENE--------------------------- 213 
                  * ********::  .:     .     .                                 
  
h_sapiens_V1      EEKGLAAEDSGGDSKDLSEVSETTESTDVKDSSEASDSAS-- 235 
c_elegans         ------------------EAYTTAKTTDDKKKNRS------- 181 
s_pombe           -----------------DELAKTVQSLALNN----------- 177 
s_cerevisiae      -----------------EKLEDDLESDLLEDIIKQGVNDIIV 238 
                                    :     ::   :.            
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at 30°C. Cells were diluted to an OD600 of 0.1 
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Endogenous, single-copy genes in 
yeast. 
 
Optical density as a measure of 
growth was normalized to the W303 
wt strain for every independent 
experiment and plotted (X). The 
median of all experiments is shown 
as a short line 
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Contemporary, yeast-based approaches to understanding human
genetic variation
Maitreya J Dunham and Douglas M Fowler
Determining how genetic variation contributes to human health
and disease is a critical challenge. As one of the most
genetically tractable model organisms, yeast has played a
central role in meeting this challenge. The advent of new
technologies, including high-throughput DNA sequencing and
synthesis, proteomics, and computational methods, has vastly
increased the power of yeast-based approaches to determine
the consequences of human genetic variation. Recent
successes include systematic exploration of the effects of gene
dosage, large-scale analysis of the effect of coding variation on
gene function, and the use of humanized yeast to model
disease. By virtue of its manipulability, small genome size, and
genetic tractability, yeast is poised to help us understand
human genetic variation.
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Introduction
With acceleration of sequencing technologies, many
human genomes are becoming available from patients,
tumors, and thousands of individuals from diverse popu-
lations. In parallel, linkage mapping, genome-wide
association strategies, and analyses of de novo mutations
are rapidly linking genomic regions to phenotypes in-
cluding disease susceptibility. However, defining which
genetic variants are causative for phenotype has become
rate-limiting. Furthermore, the abundance of rare vari-
ation means that sequencing more genomes is unlikely to
solve this problem (e.g. [1,2]). We propose that new
technologies such as high-throughput DNA sequencing,
proteomics, and computational approaches can empower
model organism genetics to fill this gap by enabling high-
throughput, generic, genome-scale functional assays for
characterizing variation in the human genome. Yeast,
especially the budding yeast S. cerevisiae, is uniquely suited
to this task because of its versatility, small genome size, and
powerful array of existing tools (reviewed in [3]). Methods
for understanding the consequences of human variation
using yeast fall into three broad categories: 1. systematic
analysis of gene dosage; 2. recreation of human variants in
their yeast orthologs; and 3. cross-species complementa-
tion and heterologous expression. In addition to enabling
direct measurement of the consequences of specific
genetic variants, work in yeast and other model organisms
will be necessary for understanding the essential under-
lying biology. These larger biological questions include the
distribution of effect sizes of genetic variants, the contri-
bution of genetic modifiers and the role of epistasis more
generally, and, of course, the fundamental molecular
mechanisms by which genes and their variants act.
Systematic analysis of gene dosage
Yeast is easily amenable to purposeful manipulation of
gene dosage, most frequently via loss of function but
increasingly by overexpression as well. Examining the
resulting phenotypes can reveal the function of the
element whose dosage is changed (Figure 1a). When
specific phenotypes are shared, connections between yeast
and human can be relatively easy to recognize. Famously,
work in yeast correctly predicted the role of the human
mismatch repair genes hPMS1, hMLH1, and hMSH2 in
hereditary non-polyposis colon cancer based on the yeast
knockouts’ mutator phenotypes [4]. More systematic
approaches have now become possible (reviewed in [5]);
for example, yeast genes involved in mitochondrial biology
were used to identify human orthologs with similar cellular
roles [6]. These early studies highlighted the power of gene
deletion to make inferences about protein function.
Large-scale studies of the consequences of gene dosage
changes are pushing this approach towards its logical
conclusion in many organisms. In yeast, a variety of tools
are available including comprehensive collections of
deletions [7,8], overexpression plasmids [9,10], and hypo-
morphic alleles [11,12]. These resources have been used
effectively to infer the function of previously unanno-
tated genes [13], understand how human drugs interact
with alterations in gene dosage [14], and determine how
gene loss relates to basic cellular processes such as meiosis
[15]. These are a small sample of the hundreds of
examples that have been successful so far. Thanks in
no small part to these model organism studies, we now
have a relatively clear idea of how loss of specific gene
functions can result in disease, and some idea of the
Available online at www.sciencedirect.com
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Learning	  ObjecRves	  
•  The	  parRcipants	  will	  be	  able	  to	  discuss	  the	  
extraordinary	  amount	  of	  variable	  expressivity	  
seen	  in	  neurodevelopmental	  	  disorders.	  
•  The	  par*cipants	  will	  plan	  ways	  in	  which	  to	  
integrate	  genomic	  and	  phenotypic	  
longitudinal	  data	  to	  prevent	  the	  
development	  of	  certain	  illnesses.	  
	  



In	  the	  year	  2014….	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Is	  orders	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And	  yet,	  remarkably:	  
•  We	  do	  not	  really	  know	  the	  expression	  of	  
preQy	  much	  ALL	  mutaRons	  in	  humans,	  as	  we	  
have	  not	  systemaRcally	  sequenced	  or	  
karyotyped	  any	  geneRc	  alteraRon	  in	  
Thousands	  to	  Millions	  of	  randomly	  selected	  
people.	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Medical genetics typically entails the detailed characterization of a patient’s phenotypes followed
by genotyping to discover the responsible gene or mutation. Here, we propose that the systematic
discovery of genetic variants associatedwith complex diseases such as autism are progressing to a
point where a reverse strategy may be fruitful in assigning the pathogenic effects of many different
genes and in determining whether particular genotypes manifest as clinically recognizable pheno-
types. This ‘‘genotype-first’’ approach for complex disease necessitates the development of large,
highly integrated networks of researchers, clinicians, and patient families, with the promise of
improved therapies for subsets of patients.
The genetic study of complex disease has
historically been difficult, meeting with
limited success and often even fewer
therapeutic advances in patient care. Un-
like Mendelian disorders, complex dis-
ease is defined as a phenotype that is
not caused by a single gene mutation
but, rather, by many individual gene
events, with a significant contribution
from environmental factors. The nature
of complex genetic diseasemakes patient
care difficult, as a clinician may never see
two individuals with the same gene muta-
tion and, therefore, the same underlying
genetic etiology. Classical approaches
to the study of complex disease have
identified patientswith similar phenotypes
and have attempted to identify the com-
mon causative mutation for this pheno-
type using association studies. Though
there have been numerous loci reported
over the last 10 years, in most cases,
much of the heritability of complex dis-
ease remains unresolved (Manolio et al.,
2009). The number of success stories
for complex neurocognitive and neuro-
behavioral disease are even fewer, with
enormous numbers of patients (>30,000)
being required to discover a small fraction
of the genetic risk using genome-wide
association study (GWAS) approaches
(McCarroll and Hyman, 2013). Complex
neurodevelopmental disorders, such as
autism, schizophrenia, bipolar disorder,
intellectual disability (ID), and devel-
opmental delay (DD), require better
approaches to link genotype to pheno-
type. In this Essay, we focus on autism
spectrum disorder (ASD)—a highly com-
plex neurodevelopmental disease with a
range of phenotypes and a large patient
base—and propose a gene-centric meth-
odology to model a streamlined approach
for subtyping autism starting with the
genotype (Schulze and McMahon, 2004).
The explosion of data from recent
exome studies (Iossifov et al., 2012; Neale
et al., 2012; O’Roak et al., 2012b; Sanders
et al., 2012) and earlier work on large copy
number variants (CNVs) (de Vries et al.,
2005; Sebat et al., 2007; Sharp et al.,
2006) have emphasized the importance
of sporadic truncating mutations in ASD,
revealing a surprising level of genetic het-
erogeneity among patients. From these
data, it has been estimated that >500
distinct loci may be related to disease
etiology in ASD, assuming a model of
sporadic protein-encoding mutations.
Interestingly, more than two decades
ago, Percy postulated that a ‘‘very wide
variety of autistic syndromes depending
on underlying etiology’’ may exist based
on his observation that a significant frac-
tion of individuals with fragile X, Rett,
and tuberous sclerosis syndromes could
be classified as having autistic features
(Percy et al., 1990). Whereas traditional
genetics approaches were entirely under-
powered to detect small subpopulations
of autism with a common mutant gene,
the advent of next-generation sequencing
technology has made it possible to begin
to systematically classify genetic sub-
types of ASD and, further, to ask whether
these define specific clinical subtypes of
ASD. For the purpose of this Essay, we
will define a ‘‘genetic subtype’’ as a gene
in which recurrent mutations show an
excess of burden in patients versus con-
trols. This is distinguished from a ‘‘molec-
ular subtype’’ that constitutes a group of
genetic subtypes that are linked together
in a common pathway (coexpression,
protein-protein interaction network, etc.)
(O’Roak et al., 2012b).
The extreme genetic heterogeneity
exemplified by autism, we believe, re-
quires a shift in the approach to studying
the genetics of complex neurological
disease. Instead of comprehensive and
exhaustive phenotyping as the first step
to reducing genetic heterogeneity, we
propose to leverage technology to genet-
ically classify subtypes of disease among
patients in whom clinical recontact is
possible. We outline three logical steps
in characterizing genetic subtypes from
the perspective of autism: (1) candidate
discovery and determination of pathoge-
nicity, (2) comprehensive clinical pheno-
typing, and (3) resolution of genetic
872 Cell 156, February 27, 2014 ª2014 Elsevier Inc.
II-1 III-2 
A	  
B	  
C	   D	  
II-­‐1	   II-­‐6	   III-­‐7	  III-­‐4	   III-­‐6	  
Clinical Evaluation of a Multiple-Gene Sequencing Panel for
Hereditary Cancer Risk Assessment
Allison W. Kurian, Emily E. Hare, Meredith A. Mills, Kerry E. Kingham, Lisa McPherson, Alice S. Whittemore,
Valerie McGuire, Uri Ladabaum, Yuya Kobayashi, Stephen E. Lincoln, Michele Cargill, and James M. Ford
Processed as a Rapid Communication manuscript
Allison W. Kurian, Meredith A. Mills,
Kerry E. Kingham, Lisa McPherson,
Alice S. Whittemore, Valerie McGuire,
Uri Ladabaum, James M. Ford, Stan-
ford University School of Medicine,
Stanford; Emily E. Hare, Yuya
Kobayashi, Stephen E. Lincoln, Michele
Cargill, InVitae, San Francisco, CA.
Published online ahead of print at
www.jco.org on April 14, 2014.
Supported by the Breast Cancer
Research Foundation, a Stanford
University Cancer Institute Develop-
mental Research Award, the Jan
Weimer Junior Faculty Chair in Breast
Oncology at Stanford University,
National Institutes of Health Clinical and
Translational Science Award No. UL1
RR025744, and InVitae.
Presented in part at the American Soci-
ety of Clinical Oncology Breast Cancer
Symposium, San Francisco, CA,
September 7-9, 2013, and at the Ameri-
can Society of Human Genetics Annual
Meeting, Boston, MA, October 22-26,
2013.
Terms in blue are defined in the glos-
sary, found at the end of this article
and online at www.jco.org.
Authors’ disclosures of potential con-
flicts of interest and author contribu-
tions are found at the end of this
article.
Corresponding author: James M. Ford,
MD, Associate Professor of Medicine,
Pediatrics and Genetics, Division of
Oncology, Stanford University School of
Medicine, CCSR Building, Room 1115,
269 Campus Dr, Stanford CA, 94305;
e-mail: jmf@stanford.edu.
© 2014 by American Society of Clinical
Oncology
0732-183X/14/3299-1/$20.00
DOI: 10.1200/JCO.2013.53.6607
A B S T R A C T
Purpose
Multiple-gene sequencing is entering practice, but its clinical value is unknown. We evaluated the
performance of a customized germline-DNA sequencing panel for cancer-risk assessment in a
representative clinical sample.
Methods
Patients referred for clinical BRCA1/2 testing from 2002 to 2012 were invited to donate a research
blood sample. Samples were frozen at !80° C, and DNA was extracted from them after 1 to 10
years. The entire coding region, exon-intron boundaries, and all known pathogenic variants in other
regions were sequenced for 42 genes that had cancer risk associations. Potentially actionable
results were disclosed to participants.
Results
In total, 198 women participated in the study: 174 had breast cancer and 57 carried germline
BRCA1/2mutations. BRCA1/2 analysis was fully concordant with prior testing. Sixteen pathogenic
variants were identified in ATM, BLM, CDH1, CDKN2A, MUTYH, MLH1, NBN, PRSS1, and SLX4
among 141 women without BRCA1/2 mutations. Fourteen participants carried 15 pathogenic
variants, warranting a possible change in care; they were invited for targeted screening
recommendations, enabling early detection and removal of a tubular adenoma by colonoscopy.
Participants carried an average of 2.1 variants of uncertain significance among 42 genes.
Conclusion
Among women testing negative for BRCA1/2 mutations, multiple-gene sequencing identified 16
potentially pathogenic mutations in other genes (11.4%; 95% CI, 7.0% to 17.7%), of which 15
(10.6%; 95% CI, 6.5% to 16.9%) prompted consideration of a change in care, enabling early
detection of a precancerous colon polyp. Additional studies are required to quantify the penetrance
of identified mutations and determine clinical utility. However, these results suggest that
multiple-gene sequencing may benefit appropriately selected patients.
J Clin Oncol 32. © 2014 by American Society of Clinical Oncology
INTRODUCTION
Clinical genetic testing for cancer-risk assessment
has become widespread over the last two decades,
with evidence-based testing guidelines for heredi-
tary breast and ovarian cancer (BRCA1 andBRCA2;
BRCA1/2), Lynch syndrome (MLH1, MSH2,
MSH6, PMS2, and EPCAM), familial adenomatous
polyposis (APC), hereditary diffuse gastric cancer
(CDH1), Li-Fraumeni syndrome (TP53), Cowden’s
syndrome (PTEN), and a few other conditions.1-4
Cancer genetic counseling and risk-reducing in-
terventions have accordingly been developed for
high penetrance, autosomal dominant conditions.
Most of these interventions, especially prophylactic
surgery, are excessive for carriers of mutations that
have uncertain pathogenicity.5-7 Recently, next-
generation technology has enabled massively paral-
lel sequencing at low cost, and panels of multiple
cancer-associated genes are newly available for clin-
ical use.8,9
Despite these advances in technology, a critical
knowledgedeficit remains about the clinical valueof
multiple-gene panels for cancer susceptibility. Ma-
jor questions include howmany andwhich genes to
sequence, whether results are sufficiently under-
stood to guide intervention, and how best to coun-
sel patients about variants of low or moderate
penetrance.8,10-12 We designed a customized germ-
line sequencing panel of 42 cancer-associated genes
and evaluated its information yield among women
referred for clinical evaluation of hereditary breast
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Major	  barriers	  to	  the	  widespread	  implementa*on	  
of	  genomic	  medicine	  in	  the	  clinic.	  	  
•  Limits	  of	  our	  current	  technology	  &	  knowledge	  
•  Lack	  of	  public	  educaRon	  	  
•  Lack	  of	  physician	  knowledge	  about	  geneRcs	  
•  Apathy	  on	  the	  part	  of	  the	  populace	  in	  terms	  of	  
prevenRve	  eﬀorts	  	  
•  Reluctance	  of	  insurance	  companies	  &	  
governments	  to	  pay	  for	  geneRc	  tesRng	  
•  Focus	  in	  our	  society	  on	  treatment,	  not	  on	  early	  
diagnosis	  and	  prevenRon	  
•  Privacy	  concerns	  
	  
“It	  is	  perhaps	  naive	  to	  expect	  that	  these	  obstacles	  can	  be	  overcome	  
within	  the	  next	  20	  years,	  and	  it	  may	  very	  well	  be	  the	  case	  that	  there	  
might	  be	  a	  50-­‐year	  Rme	  horizon	  on	  the	  secure	  implementaRon	  of	  clinical	  
genomics	  and	  individualized	  medicine.	  We	  certainly	  hope	  that	  every	  
newborn	  will	  have	  the	  vast	  majority	  of	  their	  genome	  sequenced	  and	  
digitally	  available	  by	  the	  year	  2062”.	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  analysis	  
	  
Clinical	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•  GeneRc	  architecture	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  current	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  knowledge	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Abstract
Background: To facilitate the clinical implementation of genomic medicine by next-generation sequencing, it will
be critically important to obtain accurate and consistent variant calls on personal genomes. Multiple software tools
for variant calling are available, but it is unclear how comparable these tools are or what their relative merits in
real-world scenarios might be.
Methods: We sequenced 15 exomes from four families using commercial kits (Illumina HiSeq 2000 platform and
Agilent SureSelect version 2 capture kit), with approximately 120X mean coverage. We analyzed the raw data using
near-default parameters with five different alignment and variant-calling pipelines (SOAP, BWA-GATK, BWA-SNVer,
GNUMAP, and BWA-SAMtools). We additionally sequenced a single whole genome using the sequencing and
analysis pipeline from Complete Genomics (CG), with 95% of the exome region being covered by 20 or more
reads per base. Finally, we validated 919 single-nucleotide variations (SNVs) and 841 insertions and deletions
(indels), including similar fractions of GATK-only, SOAP-only, and shared calls, on the MiSeq platform by amplicon
sequencing with approximately 5000X mean coverage.
Results: SNV concordance between five Illumina pipelines across all 15 exomes was 57.4%, while 0.5 to 5.1% of
variants were called as unique to each pipeline. Indel concordance was only 26.8% between three indel-calling
pipelines, even after left-normalizing and intervalizing genomic coordinates by 20 base pairs. There were 11% of
CG variants falling within targeted regions in exome sequencing that were not called by any of the Illumina-based
exome analysis pipelines. Based on targeted amplicon sequencing on the MiSeq platform, 97.1%, 60.2%, and 99.1%
of the GATK-only, SOAP-only and shared SNVs could be validated, but only 54.0%, 44.6%, and 78.1% of the GATK-
only, SOAP-only and shared indels could be validated. Additionally, our analysis of two families (one with four
individuals and the other with seven), demonstrated additional accuracy gained in variant discovery by having
access to genetic data from a multi-generational family.
Conclusions: Our results suggest that more caution should be exercised in genomic medicine settings when
analyzing individual genomes, including interpreting positive and negative findings with scrutiny, especially for
indels. We advocate for renewed collection and sequencing of multi-generational families to increase the overall
accuracy of whole genomes.
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Abstract
To identify previously reported disease mutations that are compatible with
extraordinary longevity, we screened the coding regions of the genomes of 44
Ashkenazi Jewish centenarians. Individual genome sequences were generated
with 309 coverage on the Illumina HiSeq 2000 and single-nucleotide variants
were called with the genome analysis toolkit (GATK). We identified 130 coding
variants that were annotated as “pathogenic” or “likely pathogenic” based on
the ClinVar database and that are infrequent in the general population. These
variants were previously reported to cause a wide range of degenerative, neo-
plastic, and cardiac diseases with autosomal dominant, autosomal recessive, and
X-linked inheritance. Several of these variants are located in genes that harbor
actionable incidental findings, according to the recommendations of the Ameri-
can College of Medical Genetics. In addition, we found risk variants for late-
onset neurodegenerative diseases, such as the APOE e4 allele that was even
present in a homozygous state in one centenarian who did not develop Alzhei-
mer’s disease. Our data demonstrate that the incidental finding of certain
reported disease variants in an individual genome may not preclude an extraor-
dinarily long life. When the observed variants are encountered in the context of
clinical sequencing, it is thus important to exercise caution in justifying clinical
decisions.
Introduction
Human genetic studies have linked many variants to
human diseases or nondisease phenotypes. How to handle
the incidental finding of a disease variant is a topic of
current discussion (Green et al. 2013a; Klitzman et al.
2013). Incidental findings often occur, when genome
sequencing data are screened for disease-causing variants
that are recorded in databases such as Online Mendelian
Inheritance in Man (OMIM) (Hamosh et al. 2005) or,
more recently, ClinVar (Landrum et al. 2014) and the
Genome Wide Association Studies (GWAS) catalog
ª 2014 The Authors. Molecular Genetics & Genomic Medicine published by Wiley Periodicals, Inc.
This is an open access article under the terms of the Creative Commons Attribution License, which permits use,
distribution and reproduction in any medium, provided the original work is properly cited.
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XLID-Causing Mutations and Associated Genes Challenged
in Light of Data From Large-Scale Human Exome Sequencing
Ame´lie Piton,1,2,4,* Claire Redin,1,2,4 and Jean-Louis Mandel1,2,3,*
Because of the unbalanced sex ratio (1.3–1.4 to 1) observed in intellectual disability (ID) and the identification of large ID-affected fam-
ilies showing X-linked segregation, much attention has been focused on the genetics of X-linked ID (XLID). Mutations causing mono-
genic XLID have now been reported in over 100 genes, most of which are commonly included in XLID diagnostic gene panels. Nonethe-
less, the boundary between true mutations and rare non-disease-causing variants often remains elusive. The sequencing of a large
number of control X chromosomes, required for avoiding false-positive results, was not systematically possible in the past. Such infor-
mation is now available thanks to large-scale sequencing projects such as the National Heart, Lung, and Blood (NHLBI) Exome
Sequencing Project, which provides variation information on 10,563 X chromosomes from the general population. We used this NHLBI
cohort to systematically reassess the implication of 106 genes proposed to be involved in monogenic forms of XLID. We particularly
question the implication in XLID of ten of them (AGTR2, MAGT1, ZNF674, SRPX2, ATP6AP2, ARHGEF6, NXF5, ZCCHC12, ZNF41,
and ZNF81), in which truncating variants or previously published mutations are observed at a relatively high frequency within this
cohort. We also highlight 15 other genes (CCDC22, CLIC2, CNKSR2, FRMPD4, HCFC1, IGBP1, KIAA2022, KLF8, MAOA, NAA10,
NLGN3, RPL10, SHROOM4, ZDHHC15, and ZNF261) for which replication studies are warranted. We propose that similar reassessment
of reported mutations (and genes) with the use of data from large-scale human exome sequencing would be relevant for a wide range of
other genetic diseases.
Introduction
Intellectual disability (ID, formerly called mental retarda-
tion) is a developmental brain disorder commonly defined
by an IQ below 70 and limitations in both intellectual
functioning and adaptive behavior. ID can originate from
environmental causes and/or genetic anomalies, and its
incidence in children is estimated to be of 1%–2%.1,2 As
a result of an excess of males affected by ID (the male-to-
female ratio is 1.3–1.4 to 1) and the identification of
many families presenting with a clear X-linked segrega-
tion, much attention has been focused for the last 20 years
on genes located on the X chromosome and thus respon-
sible for X-linked ID (XLID, previously known as XLMR)
when mutated.3,4 One of the first genes identified as
involved in XLID is FMR1 (MIM 309550), a target of the
unstable expansion mutation responsible for fragile X syn-
drome (MIM 300624); accounting for about 1%–2% of all
ID cases, this mutation still remains the most common
cause of XLID.5,6 Since then, the number of genes involved
in XLID when mutated has grown exponentially,3,7,8 from
only 11 in 1992 to 43 in 2002 and over 100 genes now
identified thank to the efforts of various teams.4,9,10 Half
of the known genes carrying mutations responsible for
XLID appear to be associated with nonsyndromic or pauci-
syndromic forms; the other half are associated with more
syndromic forms (i.e., ID associated with defined clinical
or metabolic manifestations), which facilitates the identifi-
cation of causative mutations in the same gene because
unrelated probands with comparable phenotypes can
bemore easily matched. However, the presence of ‘‘milder’’
mutations (in RPS6KA3 [RSK2, MIM 300075] or ARX [MIM
300382], for instance) and/or incomplete penetrance of
specific clinical signs in some individuals carrying muta-
tions in genes associated with syndromic ID can blur the
distinction between syndromic and nonsyndromic ID.11
Various approaches have been developed for the identi-
fication of genes and associated causative mutations
responsible for XLID (see Lubs et al.4 for a review): (1) po-
sitional cloning based on chromosomal rearrangements or
copy-number variants (CNVs) affecting the X chromo-
some, (2) screening of genes located in candidate intervals
identified via linkage analysis in large XLID-affected fam-
ilies, (3) direct sequencing of candidate genes with a func-
tion or expression pattern that suggests a role in cognition
or that fits with metabolic or clinical observations in
affected subjects, and (4) high-throughput sequencing al-
lowing screening of mutations in all protein-coding re-
gions of the genome or only in the X chromosome (exome
versus X exome).10,12–14
The validation of potentially damaging mutations in a
gene newly associated with XLID requires functional
and/or genetic analyses, especially when the identification
is based on reportingmutations in very few families or sim-
plex cases. Functional studies are uneven in pertinence
and strength. They can include direct assessment of the
mutational impact at any of the protein, cellular, or
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This	  is	  SO	  complex	  that	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“If you sequence people’s exomes you’re going to find stuﬀ,” said Gholson Lyon, 
a physician and researcher previously at the University of Utah, now at Cold 
Spring Harbor Laboratory.
As part of his research, Dr. Lyon worked with a family in Ogden, Utah. Over 
two generations, four boys had died from an unknown disease with a distinct 
combination of symptoms—an aged appearance, facial abnormalities, and devel-
opmental delay. Dr. Lyon sought to identify the genetic cause of this disease, and 
collected blood samples from 12 family members who had signed consent forms. 
The family members understood these forms to mean that they would have access 
to their results.
Dr. Lyon conducted exon capture and sequencing of the X chromosome—a 
process that analyzes specific regions of the X chromosome and is a less expensive 
alternative to whole genome sequencing—to analyze the blood samples. Dr. 
Lyon and his colleagues identified a genetic mutation, and named the disease 
Ogden Syndrome after the family’s hometown.
After Dr. Lyon and his team identified the genetic basis of Ogden Syndrome, 
one of the family members contacted him. This young mother of one daughter 
had submitted a blood sample for Dr. Lyon’s research. She had not been preg-
nant at the time, but was now four months pregnant with her second child. 
She knew that she was carrying a boy and wanted to know if she was a carrier 
of the mutation. She wanted to be able to mentally and emotionally prepare 
herself and her family.
By reexamining his research data, Dr. Lyon was able to see that the expectant 
mother was a carrier of Ogden Syndrome. This meant that her son had a 50 
percent chance of being born with the disease. Dr. Lyon could not, however, 
legally share this important information with the family because he had conducted 
the original sequencing in a research laboratory that had not satisfied federally 
mandated standards designed to ensure the accuracy of clinical genetic results.
Instead, Dr. Lyon worked to have the mutation validated at a laboratory that 
satisfied those federal standards; this involved overcoming substantial bureau-
cratic hurdles and other obstacles that held up the process. During this time, 
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the baby boy was born and died of Ogden Syndrome at four months of age. 
While knowing the results would not have changed the outcome, Dr. Lyon feels 
he should have been able to do more for the family.
Dr. Lyon has become an outspoken advocate for conducting whole genome 
sequencing in laboratories that satisfy the federal standards so that researchers 
can return results to participants, if appropriate. Dr. Lyon wants clear guid-
ance for laboratories conducting genetic research and clear language in consent 
forms that clarifies the results that participants should expect to have returned 
from the researchers.
Realizing the promise of whole genome sequencing requires widespread 
public participation and individual willingness to share genomic data and 
relevant medical information. This requires public trust that any whole 
genome sequence data shared by individuals with researchers and clinicians 
will be adequately protected. Individuals must trust that eir whole genome 
sequence d ta will not be either i tentionally or i advert ntly disclosed or 
misused. Current U.S. g vernance and oversight f genetic and genomic 
data, however, do not fully protect i dividuals from the risks associated with 
sharing their whole genome sequence data and information. 
The Genetic Information Nondiscrimination Act of 2008 (GINA) is the 
leading federal protection of genetic information, but it oﬀers only prohibi-
tion of genetic discrimination in health insurance and employment. GINA 
does not regulate access, security, and disclosure of genetic or whole genome 
sequence information across all potential users, nor does it protect against 
discrimination in other contexts. U.S. state laws on genetic information 
vary greatly in their protections of individuals, and they also fail to provide 
uniform privacy protections. In an era in which whole genome sequence data 
are increasingly stored and shared using biorepositories and databases, there 
is little to no systematic oversight of these systems. 
Ethical Principles
Laws and regulations cannot do all of the work necessary to provide suﬃcient 
privacy protections for whole genome sequence data. Individuals who obtain 
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systems and infrastructure to facilitate health information exchange so that 
data can be easily aggregated and studied.213 Integrating whole genome 
sequence data into health records within the learning health system model 
can provide researchers with more data to perform genome-wide analyses, 
which in turn can advance clinical care. Several Institute of Medicine (IOM) 
working groups have supported these goals, outlining the desirability of 
establishing a universal health information technology system and learning 
environment that engages health care providers and patients. The IOM 
reports recommend that such a system include both genomic and clinical 
information, increased interoperability of medical records systems, and 
reduced barriers to data sharing.214 The President’s Council of Advisors 
on Science and Technology identified the lack of sharing electronic health 
records—with patients, with a patient’s health care providers at other 
organizations, with public health agencies, and with researchers—as a barrier 
to improved health care.215
Recommendation 4.1
Funders of whole genome sequencing research, relevant clinical entities, 
and the commercial sector should facilitate explicit exchange of information 
between genomic researchers and clinicians, while maintaining robust data 
protection safeguards, so that whole genome sequence and health data can be 
shared to advance genomic medicine.
Performing all whole genome sequencing in CLIA-approved laboratories 
would remove one of the barriers to data sharing. It would help ensure that 
whole genome sequencing generates high-quality data that clinicians and 
researchers can use to draw clinically relevant conclusions. It would also 
ensure that individuals who obtain their whole genome sequence data could 
share them more confidently in patient-driven research initiatives, producing 
more meaningful data. That said, current sequencing technologies and those 
in development are diverse and evolving, and standardization is a substantial 
challenge. Ongoing eﬀorts, such as those by the Standardization of Clinical 
Testing working group are critical to achieving standards for ensuring the 
reliability of whole genome sequencing results, and facilitating the exchange 
and use of these data.216
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Recent advances in sequencing technology are making possible the application of large-scale genomic anal-
yses to individualized care, both in wellness and disease. However, a number of obstacles remain before ge-
nomic sequencing can become a routine part of clinical practice. One of the more signiﬁcant and
underappreciated is the lack of consensus regarding the proper environment and regulatory structure
under which clinical genome sequencing and interpretation should be performed. The continued reliance
on pure research vs. pure clinical models leads to problems for both research participants and patients in
an era in which the lines between research and clinical practice are becoming increasingly blurred. Here,
we discuss some of the ethical, regulatory and practical considerations that are emerging in the ﬁeld of geno-
mic medicine. We also propose that many of the cost and safety issues we are facing can be mitigated through
expanded reliance on existing clinical regulatory frameworks and the implementation of distributive
work-sharing strategies designed to leverage the strengths of our genomics centers and clinical interpretive
teams.
© 2013 Elsevier B.V. All rights reserved.
1. Introduction
We are entering a fascinating and uncertain period of medical his-
tory, as today's DNA sequencing technology has the potential to help
each of us direct our care and predict our future based on knowledge
of our own individual inherited and acquired genetics. However,
from a global and local economic perspective, these are lean years,
and this adds a signiﬁcant degree of uncertainty to the immediate fu-
ture of this enterprise. It is therefore incumbent upon us to show that
the personalized medical application of large-scale genomic analysis
will not just be a luxury or a burdensome cost center, but that it
truly has the potential to save both lives and health care expenses
via data-driven management, early disease detection/screening and
more efﬁcacious pharmaceutical delivery. To this end, we need to de-
termine how to move forward towards expanded clinical use of this
technology in a manner both rapid and economical, while ensuring
the integrity of the process and the safety and well-being of patients
and research participants. This will require careful thought and con-
sideration regarding the proper environment and regulatory structure
surrounding genomics, as well as the development of consensus re-
gardingwhat exactly constitutes a genetic test in the age of large-scale
genomics and informatics.
2. Paving the way for the broad implementation of clinical
genomic medicine
A report published in 2011 by the National Research Council for
the National Academy of Sciences elegantly described the major divi-
sions between the clinical and research worlds, including in regards
to large-scale genomic analyses, such as whole genome (WGS) se-
quencing. The report went on to offer suggestions for how to help
merge these two worlds, including articulating the need for a “Knowl-
edge Network” and “New Taxonomy”, with the recommendation that
pilot studies along such lines should be conducted (Anon., 2011).
However, the report did not address a critical issue related to genetic
testing, namely the rules that should govern genomic research and
clinical care as we move into the coming era of individualized medi-
cine. The United States federal government mandates that any labora-
tory performing tests on human specimens “for the purpose of
providing information for the diagnosis, prevention, or treatment of
any disease”must satisfy the conditions set forth in the Clinical Labo-
ratory Improvement Amendments (CLIA) of 1988 (Group®, 2012).
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entirely performed on Illumina equipment using one of a few library
preparation methods, with 100 base paired-end sequencing performed
in the major research sequencing centers to an average depth of 70–
100× to achieve >80% of the target region covered by 20 or more
reads. Others havemade suggestions for standardizing exome sequenc-
ing (Klein et al., 2012), and we believe it is high-time to establish such
standards, at least for exomes being sequenced from live human beings,
so that results can be returned to participants.
However, while sequencing is relatively standardizable, it is true
that many of the downstream processes are not, as bioinformatics
analyses and interpretive schemes can be extremely variable. While
the desired informatics and interpretive analysis for healthy individ-
uals might focus on alleles relevant for future disease risk, carrier sta-
tus and pharmacogenomics, genomic analyses for rare diseases might
instead focus on de novo, homozygous or X-linked disease variants,
possibly in the context of a parent–child trio or preferably in the con-
text of even larger families, including grandparents. Certain ﬁndings
seen in one patient may escape detection in another patient simply
due to differences in the basic strategy of analysis or the phenotype
of the individuals. With respect to population studies, the analytical
variation can be tremendous, with focuses ranging from ethnicity-
speciﬁc variation to variation associated with complex disease, basic
human phenotypes and evolutionary processes. The number of differ-
ent performable analyses is limited only by the imagination.While the
informed consent process for each individual study would be required
to include a discussion of the analysis details, the process can be con-
fusing for participants and easily leave them at the end unclearwheth-
er or not particular ﬁndings were investigated and frustrated by an
inability to access the data. This being the case, it would be beneﬁcial
to move towards a systemwhereby a straightforward clinical analysis
of data from research projects could be subsequently performed at a
later time, within a proper regulatory framework.
This downstream variation in informatics and interpretation raises
an important question: from the clinical standpoint, what exactly con-
stitutes a genetic laboratory test? Is it simply the analytics (the se-
quencing), or is it a combination of analytics and interpretation, or is
it the entire process from sample receipt through to the generation
and return of a report? Here, the legal deﬁnition is really quite
clear, as CLIA speciﬁcally states that a medical laboratory test is an all-
encompassing process (Anon., 2013a). The introduction to CLIA subpart
K states that “each laboratory that performsnonwaived testingmust es-
tablish and maintain written policies and procedures that implement
and monitor quality systems for all phases of the total testing process
(that is, preanalytic, analytic, and postanalytic) as well as general labo-
ratory systems” (see Table 1 for a summary of the analytic systems).
It is noteworthy that test interpretation and reporting are speciﬁ-
cally covered by the CLIA statutes and included as part of the regulated
test process. This is important because, as the community has discov-
ered, the actual sequencing has become increasingly straightforward,
whereas the true difﬁculties and pitfalls lie in the informatics, inter-
pretation and reporting. Any meaningful regulatory framework for
NGS-based diagnostics must include oversight of informatics path-
ways and interpretive criteria, as there are simply too many ways to
do informatics incorrectly, with resultant possibilities for harm to pa-
tients and participants.
This issue is beginning to get the attention of the agencies respon-
sible for overseeing clinical laboratories, now that a large number of
clinical laboratories have begun developing a variety of tests on NGS
instruments. The College of American Pathologists (CAP) has recently
released a new checklist for molecular pathology laboratories that
includes both general laboratory and test development guidelines
covering NGS wet lab practices, bioinformatics processing and data
storage and transfer practices. Additionally, the New York State De-
partment of Health Clinical Laboratory Evaluation Program (CLEP)
has issued detailed guidelines for the development and validation of
NGS cancer genomics assays (Anon., 2013b). New York is one of
two CLIA-exempt states as a result of its own state licensure regula-
tions being deemed “equal to, or more stringent than” CLIA by CMS
per CLIA subpart E, thus clinical laboratories in New York receive
their CLIA license through th tate following s ccessful state certiﬁ-
cation. The CLEP NGS oncology guidelines are quite thorough, includ-
ing requirements for quality scores, control procedures, acceptabl
numbers of sp cimens for valid tion studies and guideli es for
stablishi g read dep , accuracy, sensitivity, tc., focusing on actual
performance rather than the details of bioinformatics pipelines. Over-
all, the regulatory framework for NGS on the pure clinical side is com-
ing together, with certain aspects such as reporting criteria hopefully
being sorted out in the near future.
However, if a clinical NGS test is deﬁned by both the sequencing
and downstream informatics, and the informatics possibilities for a
standar equence are essentially limitless, how could CLIA supervi-
sion be applied to combined research and clinical genomics operations
without placi g an extreme regu atory burden on the sequencing
laboratory? Would every analysis type need to be certiﬁed, or would
a time-consuming standardized analysis be required even if it were
not needed for each p rticular peration?
6. The distributive model: an analytical-interpretive split
across genomics
Any ideal solution would allow sequencing centers to focus on
their strengths and to leverage their economies of scale, without re-
quiring them to devote their time to unnecessary informatics and in-
terpretation. How can that be achieved in keeping with the spirit of
proper CLIA oversight? As a solution, we would propose an analytic-
interpretive split (or a so-called “distributivemodel”) across both clin-
ical and research genomics. This split model simply means that one
laboratory performs analytics and then a second laboratory performs
the interpretation and reporting. Thus, together, the two laboratories
perform all the functions that make up a laboratory test. This should
be a straightforward arrangement, but while some precedent and
guidance policies exist, the regulatory structure that would govern
such a system is still evolving, as we will discuss.
The beneﬁts of enacting such a split model could be substantial,
and we believe they could be gained without signiﬁcantly burdening
our sequencing centers with undue excess costs. Under this type of
system, the basic sample processing and sequencing operation could
be standardized across clinical patients and the majority of new geno-
mics research participants. The practical effect of this split would be
to turn an exome or genome sequence into a discrete deliverable unit
that could be used for multiple downstream purposes by multiple
downstream labs. For each patient or participant, the same validated
sequencing would be performed, and that raw data, if individually
Table 1
Processes involved in a CLIA-certiﬁed genetic test.
Preanalytic system
1) Test request and specimen collection criteria
2) Specimen submission, handling and referral procedures
3) Preanalytic systems assessment
Analytic system
1) A detailed step-by-step procedure m nual
2) Test systems, equipment, instrum nts, reagents, mat rials and
supplies
3) Establishment and veriﬁcation of performance speciﬁcations
4) Maintenance and function checks
5) Calibration and calibration veriﬁcation procedures
6) Control procedures, test records, and corrective actions
7) Analytic systems assessment
Post-analytic system
1) Test report, including (among other things):
a) interpretation
b) reference ranges and normal values
2) Post-analytic systems assessment
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1.	  Sample	  CollecRon	  and	  handling	  
	  
	  
2.	  Sequencing/AnalyRcs	  
	  
	  
3.	  InterpretaRon	  
“This	  laboratory	  test	  was	  developed,	  and	  its	  performance	  characteris*cs	  
were	  determined	  by	  the	  Illumina	  Clinical	  Services	  Laboratory	  (CLIA-­‐cer*ﬁed,	  
CAP-­‐accredited).	  Consistent	  with	  laboratory-­‐developed	  tests,	  it	  has	  not	  been	  
cleared	  or	  approved	  by	  the	  U.S.	  Food	  and	  Drug	  Administra*on.	  If	  you	  have	  
any	  ques*ons	  or	  concerns	  about	  what	  you	  might	  learn	  through	  your	  genome	  
sequence	  informa*on,	  you	  should	  contact	  your	  doctor	  or	  a	  gene*c	  
counselor.	  Please	  note	  that	  Illumina	  does	  not	  accept	  orders	  for	  Individual	  
Genome	  Sequencing	  services	  from	  Florida	  and	  New	  York.”	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ABSTRACT
Background. In recent years, there has been an explosion in the number of technical
and medical diagnostic platforms being developed. This has greatly improved our
ability to more accurately, and more comprehensively, explore and characterize
human biological systems on the individual level. Large quantities of biomedical
data are now being generated and archived in many separate research and clinical
activities, but there exists a paucity of studies that integrate the areas of clinical
neuropsychiatry, personal genomics and brain-machine interfaces.
Methods. A single person with severe mental illness was implanted with the
Medtronic Reclaim® Deep Brain Stimulation (DBS) Therapy device for Obsessive
Compulsive Disorder (OCD), targeting his nucleus accumbens/anterior limb of the
internal capsule. Programming of the device and psychiatric assessments occurred
in an outpatient setting for over two years. His genome was sequenced and vari-
ants were detected in the Illumina Whole Genome Sequencing Clinical Laboratory
Improvement Amendments (CLIA)-certified laboratory.
Results. We report here the detailed phenotypic characterization, clinical-grade
whole genome sequencing (WGS), and two-year outcome of a man with severe
OCD treated with DBS. Since implantation, this man has reported steady improve-
ment, highlighted by a steady decline in his Yale-Brown Obsessive Compulsive Scale
(YBOCS) score from⇠38 to a score of⇠25. A rechargeable Activa RC neurostimula-
tor battery has been of major benefit in terms of facilitating a degree of stability and
control over the stimulation. His psychiatric symptoms reliably worsen within hours
of the battery becoming depleted, thus providing confirmatory evidence for the
eYcacy of DBS for OCD in this person.WGS revealed that he is a heterozygote for the
p.Val66Met variant in BDNF, encoding a member of the nerve growth factor family,
and which has been found to predispose carriers to various psychiatric illnesses.
He carries the p.Glu429Ala allele in methylenetetrahydrofolate reductase (MTHFR)
and the p.Asp7Asn allele in ChAT, encoding choline O-acetyltransferase, with both
alleles having been shown to confer an elevated susceptibility to psychoses. We have
found thousands of other variants in his genome, including pharmacogenetic and
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Figure 1 Sagittal and transverse computed tomography (CT) images of the brain and skull ofMA.We
show here sagittal and transverse sections taken from CT scans. Imaging was performed before (A) and
after (B) MA received deep brain stimulation surgery for his treatment refractory OCD. Two deep brain
stimulator probes can be seen to be in place from a bifrontal approach (B), with tips of the probes located
in the region of the hypothalamus. Leads traverse through the left scalp soft tissues. Streak artifact from
the leads somewhat obscures visualization of the adjacent bifrontal and left parietal parenchyma. We did
not observe any intracranial hemorrhage, mass eVect or midline shift or extra-axial fluid collection. Brain
parenchyma was normal in volume and contour.
DBS implant has contributed to any of these issues. Attempts to add fluoxetine at 80 mg
by mouth daily for two months to augment any eYcacy from the DBS and ERP were
unsuccessful, mainly due to no discernible benefit and prominent sexual side eVects. MA
still receives an injection of 37.5 mg risperidone every two weeks for his past history of
O’Rawe et al. (2013), PeerJ, DOI 10.7717/peerj.177 8/26
Commercial analysis platforms for genomic data 
No	  rare	  variants	  or	  CNVs	  with	  high	  biological	  eﬀect	  as	  related	  to	  
mental	  illness.	  	  
	  
Here	  are	  just	  3	  of	  dozens	  of	  common	  SNVs	  in	  this	  person	  that	  
have	  been	  implicated	  in	  the	  literature	  as	  predisposing	  to	  mental	  
illness.	  
Table 1 A summary of three clinically relevant alleles found in the sequencing results of MA. Variations in MTHFR, BDNF, and ChAT were
found to be of potential clinical relevance for this person as they are all implicated in contributing to the susceptibility and development of many
neuropsychiatric disorders that resemble those present within MA. A brief summary of the characteristics of each variation is shown, including the
gene name, genomic coordinates, amino acid change, zygosity, variation type, estimated population frequency and putative clinical significance.
Gene
name
Genomic
coordinates
Amino acid
change
Zygosity Variation
type
Population
frequency
Clinical significance
MTHFR chr1: 11854476 Glu> Ala heterozygous non-synon T:77% G:23% Susceptibility to psychoses, schizophrenia
occlusive vascular disease, neural tube defects,
colon cancer, acute leukemia, and methylenetetra-
hydrofolate reductase deficiency
BDNF chr11: 27679916 Val>Met heterozygous non-synon C:77% T:23% Susceptibility to OCD, psychosis, and diminished
response to exposure therapy
CHAT chr10: 50824117 Asp> Asn heterozygous non-synon G:85% A:15% Susceptibility to schizophrenia and other psy-
chopathological disorders.
be given the opportunity, like with many other traditional medical tests, to obtain “second
opinions”. For this to be possible, one must accurately describe the contents of short-read
sequencing data in terms of the existing electronic medical health standards, so that these
data can be incorporated into an electronic medical health record. Accurately describing
the contents of next generation sequencing (NGS) results is particularly critical for
clinical analysis of genomic data. However, genomics and medicine use diVerent and
often incompatible terminologies and standards to describe sequence variants and their
functional eVects. In our eVorts to treat this one person with severe mental illness, we
have implemented the GVFclin format for the variants that were discovered during the
sequencing of his whole genome (see File S12). We hope to eventually incorporate his
genetic data into his electronic health record if and when the VistA health information
system (HIS) (Conn, 2011; Protti & Groen, 2008; Kuzmak & DayhoV, 1998; Brown et al.,
2003) is upgraded to allow entry of such data.We did already counsel MA regarding several
genetic variants that may be clinically relevant to predisposing him to his psychiatric
disorder (Biesecker & Peay, 2013).
Returning genetic results
There is considerable controversy in the field of medical genetics concerning the extent of
return of genetic results to people, particularly in the context of “secondary”, “unrelated”,
“unanticipated” or “incidental” findings stemming from new high-throughput sequencing
techniques (Lyon, 2012c). Some people have concerns regarding the clinical utility
of much of the data, and in response have advocated for selectively restricting the
returnable medical content. One such set of recommendations has been provided by
the American College ofMedical Genetics which recently released guidelines in which they
recommended the “return of secondary findings” for 57 genes, without detailed guidance
for the rest of the genome (Green et al., 2013). These types of recommendations take
a more paternalistic approach in returning test results to people, and generally involve
a deciding body of people that can range in size from a single medical practitioner to
a committee of experts. We believe that anyone should be able to access and manage
O’Rawe et al. (2013), PeerJ, DOI 10.7717/peerj.177 16/26
Ripke	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  (2013)	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  (2013)	  Nature	  GeneRcs	  
PharmacogeneRcs	  
u  MA	  is	  homozygous	  for	  a	  p.Ile359Leu	  change	  in	  CYP2C9,	  and	  this	  variant	  
has	  been	  linked	  to	  a	  reducRon	  in	  the	  enzymaRc	  acRvity	  of	  CYP2C9,	  a	  
member	  of	  the	  cytochrome	  P450	  superfamily	  of	  enzymes.	  	  
	  
u  FluoxeRne	  is	  commonly	  used	  in	  the	  treatment	  of	  OCD..	  	  
u  CYP2C9	  acts	  to	  convert	  ﬂuoxeRne	  to	  R-­‐norﬂuoxeRne,	  and	  so	  MA	  may	  not	  
be	  able	  to	  adequately	  biotransform	  ﬂuoxeRne.	  
u  It	  is	  notable	  that	  MA	  had	  no	  response	  to	  an	  80	  mg	  daily	  dose	  of	  ﬂuoxeRne.	  
u  However,	  CYP2C9	  does	  not	  play	  a	  rate-­‐limiRng	  role	  for	  other	  SSRIs	  or	  
clomipramine	  
Clinical	  Validity	  with	  Worldwide	  
Human	  GeneRc	  VariaRon	  “database”?	  
Pa*entsLikeMe	  
100,000	  Bri*sh	  Genomes	  
Clinical	  Validity?	  
	  
This	  is	  SO	  complex	  that	  the	  only	  solid	  
way	  forward	  is	  with	  a	  “networking	  of	  
science”	  model,	  i.e.	  online	  database	  
with	  genotype	  and	  phenotype	  
longitudinally	  tracked	  for	  thousands	  of	  
volunteer	  families.	  
Pa*entsLikeMe	  
Learning	  ObjecRves	  
•  The	  parRcipants	  will	  be	  able	  to	  discuss	  the	  
extraordinary	  amount	  of	  variable	  expressivity	  
seen	  in	  neurodevelopmental	  	  disorders.	  
•  The	  parRcipants	  will	  plan	  ways	  in	  which	  to	  
integrate	  genomic	  and	  phenotypic	  
longitudinal	  data	  to	  prevent	  the	  development	  
of	  certain	  illnesses.	  
	  
Summary	  
•  Ancestry,	  i.e.	  geneRc	  background,	  maQers.	  
•  CollecRvely,	  we	  need	  to	  improve	  the	  accuracy	  
of	  “whole”	  genomes,	  and	  also	  enable	  the	  
sharing	  of	  genotype	  and	  phenotype	  data	  
broadly,	  among	  researchers,	  the	  research	  
parRcipants	  and	  others.	  
•  We	  need	  to	  sequence	  accurate	  whole	  
genomes	  of	  large	  pedigrees,	  and	  then	  
construct	  super-­‐family	  structures.	  
	  
The	  End–	  extra	  slides	  to	  follow	  
A	  prisoner	  at	  Dartmoor	  is	  forced	  to	  turn	  a	  crank	  handle	  repeatedly	  as	  a	  form	  of	  
punishment,	  as	  depicted	  in	  an	  illustraRon	  dated	  1884.	  
“There	  are	  ~12	  billion	  nucleoRdes	  in	  every	  cell	  of	  the	  human	  body,	  and	  there	  are	  
~25-­‐100	  trillion	  cells	  in	  each	  human	  body.	  Given	  somaRc	  mosaicism,	  epigeneRc	  
changes	  and	  environmental	  diﬀerences,	  no	  two	  human	  beings	  are	  the	  same,	  
parRcularly	  as	  there	  are	  only	  ~7	  billion	  people	  on	  the	  planet”.	  	  
Sequencing	  of	  42	  genes,	  captured	  with	  Agilent	  custom	  capture	  
The	  enRre	  coding	  region,	  exon-­‐intron	  boundaries	  (±	  10	  bp),	  and	  other	  regions	  were	  
targeted	  and	  captured	  using	  Agilent	  SureSelect	  custom	  RNA	  probes	  and	  Integrated	  
DNA	  Technologies	  xGen	  Lockdown	  custom	  DNA	  probes.	  	  
	  
QuanRﬁed	  libraries	  were	  sequenced	  on	  the	  Illumina	  MiSeq	  plazorm	  using	  the	  2	  x	  151	  
bp	  conﬁguraRon	  to	  at	  least	  400x	  average	  coverage.	  BioinformaRcs	  and	  data	  quality	  
control	  followed	  the	  Genome	  Analysis	  Toolkit	  best-­‐pracRces,	  with	  addiRonal	  
algorithms	  to	  detect	  larger	  inserRons,	  deleRons,	  and	  duplicaRons.	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A B S T R A C T
Purpose
Multiple-gene sequencing is entering practice, but its clinical value is unknown. We evaluated the
performance of a customized germline-DNA sequencing panel for cancer-risk assessment in a
representative clinical sample.
Methods
Patients referred for clinical BRCA1/2 testing from 2002 to 2012 were invited to donate a research
blood sample. Samples were frozen at !80° C, and DNA was extracted from them after 1 to 10
years. The entire coding region, ex n-i tron b undaries, and all known pathogenic variants in other
regions were sequenced for 42 genes that had cancer risk associations. Potentially actionable
results were disclosed to participants.
Results
In total, 198 women participated in the study: 174 had breast cancer and 57 carried germline
BRCA1/2mutations. BRCA1/2 analysis wa fully concordant with prior tes ing. Sixtee pathogenic
variants were identified in ATM, BLM, CDH1, CDKN2A, MUTYH, MLH1, NBN, PRSS1, and SLX4
among 141 women without BRCA1/2 mutations. Fourteen participants carried 15 pathogenic
variants, warranting a possible change in care; they were invited for targeted screening
recommendations, enabling early detection and removal of a tubular adenoma by colonoscopy.
Participants carried an average of 2.1 variants of uncertain significance among 42 genes.
Conclusion
Among women testing negative for BRCA1/2 mutations, multiple-gene sequencing identified 16
potentially pathogenic mutations in other genes (11.4%; 95% CI, 7.0% to 17.7%), of which 15
(10.6%; 95% CI, 6.5% to 16.9%) prompted consideration of a change in care, enabling early
detection of a precancerous colon polyp. Additional studies are required to quantify the penetrance
of identified mutations and determine clinical utility. However, these results suggest that
multiple-gene sequencing may benefit appropriately selected patients.
J Clin Oncol 32. © 2014 by American Society of Clinical Oncology
INTRODUCTION
Clinical genetic testing for cancer-risk assessment
has become widespread over the last two decades,
with evidence-based testing guidelines for heredi-
tary breast and ovarian cancer (BRCA1 andBRCA2;
BRCA1/2), Lynch syndrome (MLH1, MSH2,
MSH6, PMS2, and EPCAM), familial adenomatous
polyposis (APC), hereditary diffuse gastric cancer
(CDH1), Li-Fraumeni syndrome (TP53), Cowden’s
syndrome (PTEN), and a few other conditions.1-4
Cancer genetic counseling and risk-reducing in-
terventions have accordingly been developed for
high penetrance, autosomal dominant conditions.
Most of these interventions, especially prophylactic
surgery, are excessive for carriers of mutations that
have uncertain pathogenicity.5-7 Recently, next-
generation technology has enabled massively paral-
lel sequencing at low cost, and panels of multiple
cancer-associated genes are newly available for clin-
ical use.8,9
Despite these advances in technology, a critical
knowledgedeficit remains about the clinical valueof
multiple-gene panels for cancer susceptibility. Ma-
jor questions include howmany andwhich genes to
sequence, whether results are sufficiently under-
stood to guide intervention, and how best to coun-
sel patients about variants of low or moderate
penetrance.8,10-12 We designed a customized germ-
line sequencing panel of 42 cancer-associated genes
and evaluated its information yield among women
referred for clinical evaluation of hereditary breast
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Beyond	  our	  Kuhnian	  inheritance	  
A	  recent	  lecture	  by	  Prof	  Greg	  Radick	  quesRons	  our	  scienRﬁc	  inheritance,	  
through	  textbook	  histories	  of	  geneRcs	  and	  Thomas	  Kuhn's	  legacy	  
hQp://www.guardian.co.uk/science/the-­‐h-­‐word/2012/aug/28/thomas-­‐
kuhn	  
Walter	  Frank	  Raphael	  Weldon	  
Vs.	  	  
William	  Bateson	  
Forthcoming	  by	  Greg	  Radick.	  Scholarly	  ediRon	  of	  W.	  F.	  R.	  Weldon's	  Theory	  of	  
Inheritance	  (1904-­‐1905),	  coedited	  with	  Annie	  Jamieson.	  
Mendel’s laws of alternative inheritance in peas 29 
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16p11.2 duplication 
Fernandez B A et al. J Med Genet 2010;47:195-203 
©2010 by BMJ Publishing Group Ltd 
Clinical photographs. (e) Proband 5 who has a maternally inherited 
duplication. (f) Proband 5 (note smooth philtrum) and her healthy duplication 
positive sister. (g) Duplication positive mother of proband 5, who also has a 
smooth philtrum. (h) Proband 6 (inherited duplication and oliogohydramnios 
sequence). Note her frontal bossing, receding hairline, hypoplastic 
supraorbital ridges and smooth philtrum. (i) Proband 6's right hand showing 
fifth finger clinodactyly. 	  
Master	  Cra{sman	  
Most	  famously	  designed	  The	  Great	  
Eastern,	  a	  10	  foot	  long	  model	  ship	  
with	  incredible	  detail.	  
	  
Deaf	  and	  nearly	  mute	  –	  Nonverbal,	  
Obsessed	  with	  one	  topic	  of	  
building	  things.	  
Thought	  to	  be	  mentally	  retarded.	  
Usually	  quiet	  and	  reserved,	  but	  
someRmes	  was	  intolerant	  of	  
advice,	  suspicious	  of	  strangers,	  and	  
ill-­‐tempered	  and	  violent.	  
“The	  clinical	  and	  pathological	  
evidence	  of	  a	  pervasive	  
developmental	  disorder	  points	  to	  a	  
retrospecRve	  diagnosis	  of	  auRsm.”	  
Historical 
The Victorian genius of Earlswood - a 
review of the case of James Henry Pullen 
Caoimhghin S Breathnach, Conor Ward 
Summary 
London born James Henry Pullen (1836-1915) was 
admitted to Essex Hall in Colchester, an institution catering 
for learning disability, at the age of 13. Here his artistic 
talent was spotted before he moved two years later to 
Earlswood Asylum for Idiots, where he was apprenticed to 
woodworking. Such was his manual skill he was eventually 
employed making furniture for the asylum. His artistic 
propensity was similarly encouraged and although he never 
mastered coherent speech he has left a pictorial 
autobiography of some distinction. At observation he 
underwent detailed examination by Frederich Sano (1871-
1946), particular attention being paid to tokens of arrested 
development. The clinical and pathological evidence of a 
pervasive developmental disorder points to a retrospective 
diagnosis of autism. 
Key words: History; Autism; Victorian genius; Learning 
disability; Developmental disorder. 
Introduction 
In 1870 Sequin described children who had 'a useless 
protrusion of a single faculty accompanied by a woeful 
general impotence'.' Langdon Down introduced the term 
idiots savants to describe them.' The first idiot savant recog-
nised in England was Jedediah Buxton, an illiterate 
Derbyshire farmhand who could multiply two 39 digit 
numbers.3 Of the seven cases described by Langdon Down, 
the best known was James Henry Pullen, known colloquially 
as the Genius of Earlswood. Langdon Down's identification 
of the syndrome had previously been referred to in 1865.' 
Clinical history 
Pullen's parents were first cousins. They lived in Peckham 
in south London. Of 13 children six died in infancy and only 
three survived into adult life.' His brother William too, also 
cared for in an institution, had exceptional artistic skills. James 
Henry combined primitive speech with sign language. He 
could not write in coherent sentences, but he drew over 80 
sketches illustrating his life. These present a unique life story. 
Boats fascinated him from an early age. Wearing skirts, and 
not yet in breeches, he is seen at the age of nine years 
making a crude model ship from a wooden box. (Figure 1, left 
*Caoimhghin 5 Breathnach, MD, PhD, 
Con or Ward, MD, PhD, FRCPl, Departments of Anatomy & 
Physiology, Paediatrics and Maurice Kennedy Research Centre 
for Emeritus Staff, NUl University College Dublin, Ireland. 
*Correspondence 
SUBMlTIED: MARCH 11, 2005. ACCEPTED: OCTOBER 20. 2005. 
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pane1. Boys usually graduated to wearing breeches at the 
age of six years. Assuming that he inscribed the correct date 
his being still unbreeched at this late age suggests that he 
was seen in the family to have failed to reach an appropriate 
developmental age. The next year he watches an adult, 
maybe his father, sailing a crude three-masted sailing ship -
possibly his improved design- in a pond (Figure 1, middle 
pane1. When he was 12 he visited London. To him it was not 
a city of roads and shops and carriages but a great waterway 
alive with sailing activity (Figure 1, right pane1. In 1901 his 
sister, Mrs Earwicker, set out her memory of his early life. His 
first word was 'muvver'. No school would take him because 
he seemed to be unable to learn. He spent his time at home 
making ships from firewood, cotton and pins. In 1848, aged 
13, he was admitted to Essex Hall in Colchester, an institu-
tion catering for learning disability.' 
Essex Hall which later became the Royal Eastern Counties 
Asylum, was a charity set up by Rev Andrew Reed. It was 
here that his artistic talent was uncovered. In his pictorial 
autobiography he shows himself in 1848 drawing at a school 
table. There is no other young person in the picture, suggest-
ing that he was being taught on his own outside school hours 
(Figure 2, left pane1. The time on the clock is 1.45, school 
finished at 1.00. On this assumption the benign female pres-
ence is likely to be that of Mrs Sarah Pearce, identified in the 
Census of 1851 as the 38-year-old schoolmistress. Was it 
she who opened up new artistic horizons for him? The follow-
ing year, by which time he had learned to write his surname, 
he went on the Essex Hall outing to Walton-on-the-Naze. He 
portrayed a man leading the way towards the harbour. The 
masts of a ship stand out over the promenade wall. Mrs 
Pearce's husband Henry, a porter aged 40, may have been 
his guide. 
In 1850 James was moved to the Earlswood Asylum for 
Idiots, another institution set up by Andrew Reed. The Essex 
Hall educational programme had been very progressive,' and 
the young man portrays himself looking sadly back at Essex 
Hall and at his collection of 1 2 pictures, three of them depict-
ing boats (Figure 2, middle pane1. The configuration of the 
window does not match the shape of the windows in a 
contemporary sketch of Essex hall, suggesting that his work 
had been put on display in another location. 
He was put into the school at Earlswood, but his self-
portrait of 1851 is of a boy with his head buried in the tearful 
despair of failure (Figure 2, right pane1. By 1852, however, 
he was apprenticed to woodwork and boatmaking, and at his 
second attempt he produced a three-masted ship which he 
thought good enough to present to his teacher as a mark of 
appreciation (Figure 3, left pane1. His apprenticeship to 
woodworking led to the progressive complexity of his model-
ling especially after 1859. John Langdon Down, the newly 
r 
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Sibling	  Defense	  Theory	  
•  Defense	  or	  modiﬁer	  Genes?	  –	  mutaRons	  that	  
somehow	  protect	  against	  or	  modify	  the	  
eﬀects	  of	  a	  primary	  mutaRon.	  
•  Or,	  can	  female	  gender	  also	  somehow	  be	  
protecRve	  with	  certain	  mutaRons?	  
•  Henry	  Pullen	  was	  one	  of	  13	  children,	  but	  only	  
3	  lived	  to	  adult	  life.	  His	  brother,	  William,	  was	  
also	  insRtuRonalized	  and	  had	  excepRonal	  
arRsRc	  skills.	  Their	  parents	  were	  ﬁrst	  cousins.	  
=ASD	  
=Odd,	  potenRal	  
broader	  
phenotype	  
=ADHD	  =ASD	  
=Odd,	  potenRal	  
broader	  
phenotype	  
New	  Syndrome	  with	  Mental	  
RetardaRon,	  “AuRsm”,	  “ADHD”	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
Likely	  X-­‐linked	  or	  Autosomal	  Recessive,	  with	  X-­‐linked	  being	  supported	  by	  extreme	  X-­‐
skewing	  in	  the	  mother	  	  
1.5	  years	  old	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  3.5	  years	  old 	  	  
3	  years	  old	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  5	  years	  old
	  	  
Dysmorphic	  
Mental	  RetardaRon	  
“auRsm”	  
“ADHD”	  
Hearing	  diﬃculRes	  
Workup	  Ongoing	  for	  past	  10	  years	  
•  Numerous	  geneRc	  tests	  negaRve,	  including	  
negaRve	  for	  Fragile	  X	  and	  MANY	  candidate	  
genes.	  
•  Found	  one	  missense	  mutaRon	  in	  a	  known	  
mental	  retardaRon	  gene,	  but	  the	  mutaRon	  is	  a	  
very	  conservaRve	  nonsynonymous	  Asp	  to	  Glu.	  
Is	  it	  relevant	  or	  not?	  What	  about	  the	  whole	  
rest	  of	  the	  genome?	  
Sequenced	  whole	  genomes	  of	  Mother,	  Father	  
and	  Two	  Boys,	  using	  Complete	  Genomics	  
•  Sequenced	  “whole”	  genomes	  to	  obtain	  noncoding	  and	  
other	  non-­‐exonic	  regions.	  
•  No	  obvious	  pathogenic	  CNVs	  –	  microarrays	  normal.	  
•  ~6	  million	  variants	  total	  in	  the	  4	  people	  diﬀerent	  from	  
Hg19	  reference	  genome.	  
•  No	  homozygous	  autosomal	  recessive	  mutaRons	  found.	  
•  No	  Nonsense/Frameshi{	  mutaRons	  in	  both	  boys.	  
•  2	  mutaRons	  present	  in	  mother	  and	  two	  boys,	  on	  X-­‐
chromosome,	  not	  in	  father,	  not	  in	  dbSNP135,	  not	  in	  
1000Genomes	  April	  2012	  release,	  and	  not	  in	  NHLBI	  
6500	  Exomes	  
	  
2	  mutaRons	  present	  in	  mother	  and	  two	  boys,	  on	  
X-­‐chromosome,	  not	  in	  father,	  not	  in	  dbSNP135,	  
not	  in	  1000Genomes	  April	  2012	  release,	  and	  not	  
in	  NHLBI	  6500	  Exomes	  
	  
•  Nonsyn	  SNV	  	  	  ZNF41	  	  	  	  c.1191C>A	  	  p.Asp397Glu	  	  
	  	  
•  Nonsyn	  SNV	  	  	  TAF1	  	  	  	  	  	  	  c.4010T>C	  	  p.Ile1337Thr	  	  
	  
TAF1	  RNA	  polymerase	  II,	  TATA	  box	  binding	  protein	  
(TBP)-­‐associated	  factor,	  250kDa	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Mutations in the ZNF41 Gene Are Associated with Cognitive Deficits:
Identification of a New Candidate for X-Linked Mental Retardation
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Nonsyndromic X-linkedmental retardation (MRX) is defined by anX-linked inheritance pattern of low IQ, problems
with adaptive behavior, and the absence of additional specific clinical features. The 13 MRX genes identified
to date account for less than one-fifth of all MRX, suggesting that numerous gene defects cause the disorder in
other families. In a female patient with severe nonsyndromic mental retardation and a de novo balanced translocation
t(X;7)(p11.3;q11.21), we have cloned the DNA fragment that contains the X-chromosomal and the autosomal break-
point. In silico sequence analysis provided no indication of a causative role for the chromosome 7 breakpoint in
mental retardation (MR), whereas, on the X chromosome, a zinc-finger gene, ZNF41, was found to be disrupted.
Expression studies indicated that ZNF41 transcripts are absent in the patient cell line, suggesting that the mental
disorder in this patient results from loss of functional ZNF41. Moreover, screening of a panel of patients with
MRX led to the identification of two other ZNF41 mutations that were not found in healthy control individuals.
A proline-to-leucine amino acid exchange is present in affected members of one family with MRX. A second family
carries an intronic splice-site mutation that results in loss of specific ZNF41 splice variants. Wild-type ZNF41
contains a highly conserved transcriptional repressor domain that is linked to mechanisms of chromatin remodeling,
a process that is defective in various other forms of MR. Our results suggest that ZNF41 is critical for cognitive
development; further studies aim to elucidate the specific mechanisms by which ZNF41 alterations lead to MR.
Introduction
Developmental delay, also referred to as “mental retar-
dation” (MR), affects an estimated 2%–3% of the popu-
lation (Chelly and Mandel 2001). Although the etiology
of MR is complex and poorly understood, recent inves-
tigations have highlighted the importance of genetic fac-
tors in cognitive development. In particular, studies of the
X chromosome have confirmed that there are numerous
specific monogenic forms of MR. Of significant historical
importance is the recognition of fragile X syndrome
(FRAXA) and the identification of the FMR1 gene (MIM
309550). FRAXA is caused by a CGG repeat expansion
in the FMR1 5′ UTR, which is then abnormally methyl-
ated. Accounting for 2%–2.5% of the established X-
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linked forms of MR (XLMR), this syndrome is the most
common cause of XLMR known at present (for review,
see Jin and Warren [2003]). XLMR is now divided into
two subgroups: syndromic XLMR (MRXS), which in-
cludes FRAXA and other MR-associated disorders that
can be defined by a set of specific clinical features, and
MRX, which includes all X-linked forms ofMR forwhich
the only consistent clinical feature is MR. To date, 30
genes responsible for MRXS and 13 genes responsible for
MRX have been cloned (Frints et al. 2002; Hahn et al.
2002; Vervoort et al. 2002). The recent discovery that
mutations in ARX (MIM 300382)—the human homo-
logue of the Drosophila gene Aristaless—are responsible
for syndromic MRX with infantile spasms, Partington
syndrome (MIM 309510), and MRX (Bienvenu et al.
2002; Stromme et al. 2002) clearly illustrates that mu-
tations in a single disease gene may result in a relatively
broad spectrum of clinical features. This phenomenon has
been observed for an increasing number of genes impli-
cated in bothMRXS andMRX, includingMECP2 (MIM
300005) (Amir et al. 1999; Couvert et al. 2001; Yntema
et al. 2002), AGTR2 (MIM 300034) (Vervoort et al.
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linked forms of MR (XLMR), this syndrome is the most
common cause of XLMR known at present (for review,
see Jin and Warren [2003]). XLMR is now divided into
two subgroups: syndromic XLMR (MRXS), which in-
cludes FRAXA and other MR-associated disorders that
can be defined by a set of specific clinical features, and
MRX, which includes all X-linked forms ofMR forwhich
the only consistent clinical feature is MR. To date, 30
genes responsible for MRXS and 13 genes responsible for
MRX have been cloned (Frints et al. 2002; Hahn et al.
2002; Vervoort et al. 2002). The recent discovery that
mutations in ARX (MIM 300382)—the human homo-
logue of the Drosophila gene Aristaless—are responsible
for syndromic MRX with infantile spasms, Partington
syndrome (MIM 309510), and MRX (Bienvenu et al.
2002; Stromme et al. 2002) clearly illustrates that mu-
tations in a single disease gene may result in a relatively
broad spectrum of clinical features. This phenomenon has
been observed for an increasing number of genes impli-
cated in bothMRXS andMRX, includingMECP2 (MIM
300005) (Amir et al. 1999; Couvert et al. 2001; Yntema
et al. 2002), AGTR2 (MIM 300034) (Vervoort et al.
•  KRAB	  (Kruppel-­‐associated	  box)	  domain	  -­‐A	  box.	  
•  The	  KRAB	  domain	  is	  a	  transcripRon	  repression	  module,	  found	  
in	  a	  subgroup	  of	  the	  zinc	  ﬁnger	  proteins	  (ZFPs)	  of	  the	  C2H2	  
family,	  KRAB-­‐ZFPs.	  KRAB-­‐ZFPs	  comprise	  the	  largest	  group	  of	  
transcripRonal	  regulators	  in	  mammals,	  and	  are	  only	  found	  in	  
tetrapods.	  	  
•  The	  KRAB	  domain	  is	  a	  protein-­‐protein	  interacRon	  module	  
which	  represses	  transcripRon	  through	  recruiRng	  corepressors.	  
The	  KAP1/	  KRAB-­‐AFP	  complex	  in	  turn	  recruits	  the	  
heterochromaRn	  protein	  1	  (HP1)	  family,	  and	  other	  chromaRn	  
modulaRng	  proteins,	  leading	  to	  transcripRonal	  repression	  
through	  heterochromaRn	  formaRon.	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Figure 4 A, Pedigree of family P13, with sequence corresponding to the prolinerleucinemutation (left to right): unrelated control individual,
mother (II:1), index patient (III:2), and brother of the index patient (III:1). For the potentially affected female cousin (individual III-4) (indicated
with an asterisk [*]), no clinical data are available. Affected nucleotides are indicated with black arrows. B, Pedigree for family P42, with
sequence chromatograms indicating the splice-site mutation in affected individuals (left to right): father (I:1), mother (I:2), index patient (II:1),
and mildly affected sister (II:2). Uppercase letters indicate coding sequence; affected nucleotides are indicated with black arrows.
a diagnosis of mild MR. He was born at term (by Ce-
sarean section), with a birth weight of 3,000 g (10th–25th
percentile) and a length of 51 cm (50th percentile). He
walked at age 12–13 mo and reached early milestones
within the normal time frame; however, he exhibited a
severe language delay. He first made two-word associa-
tions at age 3 years and was first speaking in simple
phrases at age 4 years 6 mo. At age 8 years, he was 135
cm tall (90th percentile) and had a head circumference
of 53 cm (75th percentile). He had no additional dys-
morphic or neurological symptoms, and results of
screening for fragile X were negative. At age 10 years 3
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Figure 6 Northern blot hybridization of ZNF41, by use of a probe corresponding to nucleotides 621–1099 of ZNF41 transcript variant
1. A, Adult tissues (left to right): heart, brain, placenta, lung, liver, skeletal muscle, kidney, and pancreas. B, Fetal tissues (left to right): brain,
lung, liver, and kidney.C,Adult brain structures (left to right): amygdala, caudate nucleus, corpus callosum, hippocampus, whole brain, substantia
nigra, and thalamus. Black arrowheads highlight the presence of a novel 6-kb transcript. Actin (A and C) or GAPDH (B) served as controls
for RNA loading.
sible for sequence-specific DNA binding. ZNF41, absent
in our patient, is a member of the subfamily of Krueppel-
type zinc-finger proteins harboring a highly conservedN-
terminal domain known as the Krueppel-associated box
(KRAB). Although the specific functions of ZNF41 are
not fully understood, various related genes play an es-
tablished and important role in human development and
disease (Ladomery and Dellaire 2002). In another female
patient with severe MRX and a balanced translocation,
the disorder probably resulted from the disruption of a
related X-chromosomal zinc-finger gene (Lossi et al.
2002). The X-chromosome breakpoint was located just
upstream of the Krueppel-like factor 8 (KLF8 [MIM
300286]), also known as the “ZNF741 gene,” and it was
confirmed that KLF8 transcripts were absent in the pa-
tient cell line. The Wilms tumor suppressor gene WT1
(MIM 194070), which harbors four Krueppel-type zinc
fingers, has been implicated in several urogenital devel-
opmental disorders, including WAGR syndrome (MIM
194072), which is associated with MR (Call et al. 1990;
Rose et al. 1990; Gessler et al. 1992). Of particular rel-
evance, however, are the biochemical studies that high-
light the links between the highly conserved KRAB/ZFP
subfamily of zinc-finger proteins and chromatin remod-
eling. Many disorders, several of which are associated
with MR, have been linked to defects in processes that
govern chromatin structural modification (Hendrich and
Bickmore 2001), suggesting that chromatin structural
regulationmay play a specific and important role in path-
ways critical for mental function.
Repression of transcription by a KRAB/ZFP requires
binding of the corepressor KAP-1 (also known as
“TIF1b” and “KRIP-1” [MIM 601742]) (Friedman et
al. 1996; Kim et al. 1996; Moosmann et al. 1996; Peng
et al. 2000a, 2000b). KAP-1 is a molecular scaffold that
coordinates gene-specific silencing by recruiting both
heterochromatin-associated proteins (Ryan et al. 1999)
and by interacting with the novel histone H3 Lys9–
specific methyltransferase SETDB1 (MIM 604396)
(Schultz et al. 2002). It is interesting that, within the
primary sequence of SETDB1, Schultz et al. (2002) iden-
tified a methyl CpG–binding domain that is related to
the domain found in the methyl CpG binding protein
MeCP2, which is mutated both in patients with Rett
syndrome (MIM 312750) (Amir et al. 1999) and in
patients with MRX (Couvert et al. 2001; Yntema et al.
2002). Like ZNF41, MECP2 is ubiquitously expressed;
yet loss of functional protein results in a neurological
phenotype. Although the mechanism by whichMECP2
mutations cause MR is not clear, it is well established
that MeCP2 binds to methylated CpGs and represses
transcription (for review, see Ballestar and Wolffe
[2001]), and it has recently been shown that MeCP2
associates with an unidentified methyltransferase that
specifically methylates Lys9 of histone H3 (Fuks et al.
2003), as does the KAP-1/KRAB/ZFP binding partner
SETDB1.
Further characterization of the KRAB/KAP-1 repres-
sor module has indicated that, in addition to the KRAB
domain, a bipartite domain of the plant homeodomain
(PHD) finger and a bromodomain, located within the C-
terminal portion of KAP-1, are also required for effective
gene silencing (Schultz et al. 2002). It is interesting that
the point mutations in that study were modeled after
naturally occurring mutations in the PHD finger of the
human ATRX gene, which has been implicated in both
X-linked a-thalassemia/MR syndrome (MIM 301040)
(Gibbons et al. 1995) and Juberg-Marsidi syndrome
(MIM 309590), which is also associated with MR (Vil-
lard et al. 1996a). In light of the fact that the PHD
Proving	  Causality	  
•  Will	  need	  to	  ﬁnd	  a	  second,	  unrelated	  family	  with	  same	  exact	  mutaRon	  and	  
similar	  phenotype.	  
•  Can	  also	  p rform	  in	  vitro/i 	  vivo	  studies	  an 	  struct ral	  mod ling,	  and	  make	  
knock-­‐in	  mice	  and/or	  test	  in	  zebraﬁsh,	  etc…	  for	  biological	  funcRon.	  
Genotype	  First,	  Phenotype	  Second	  
AND	  Longitudinally	  
Phenotypic variability and genetic susceptibility
to genomic disorders
Santhosh Girirajan and Evan E. Eichler∗
Department of Genome Sciences, Howard Hughes Medical Institute, University of Washington School of Medicine,
PO Box 355065, Foege S413C, 3720 15th Avenue NE, Seattle, WA 98195, USA
Received July 28, 2010; Revised July 28, 2010; Accepted August 24, 2010
The duplication architecture of the human genome predisposes our species to recurrent copy number
variation and disease. Emerging data suggest that this mechanism of mutation contributes to both
common and rare diseases. Two features regarding this form of mutation have emerged. First, common
structural polymorphisms create susceptible and protective chromosomal architectures. These structural
polymorphisms occur at varying frequencies in populations, leading to different susceptibility and ethnic
predilection. Second, a subset of rearrangements shows extreme variability in expressivity. We propose
that two types of genomic disorders may be distinguished: syndromic forms where the phenotypic features
are largely invariant and those where the same molecular lesion associates with a diverse set of diagnoses
including epilepsy, schizophrenia, autism, intellectual disability and congenital malformations. Copy number
variation analyses of patient genomes reveal that disease type and severity may be explained by the occur-
rence of additional rare events and their inheritance within families. We propose that the overall burden of
copy number variants creates differing sensitized backgrounds during development leading to different
thresholds and disease outcomes. We suggest that the accumulation of multiple high-penetrant alleles
of low frequency may serve as a more general model for complex genetic diseases, posing a significant
challenge for diagnostics and disease management.
INTRODUCTION
Genomic disorders were originally described as large deletions
and duplications that are highly penetrant, mostly de novo in
origin, and typically identified in affected individuals with intel-
lectual disability/multiple congenital malformations. Some
examples include Smith–Magenis syndrome (MIM: 182290),
DiGeorge/velocardiofacial syndrome (MIM: 188400, 192430)
andWilliams–Beuren syndrome (MIM: 194050). These classi-
cal genomic disorders have been well characterized in the past
two decades with genotype–phenotype correlation studies
implicating causative genes, mouse models recapitulating the
human clinical features, and standardized management proto-
cols and support groups established.
Application of higher definition molecular techniques,
including single-nucleotide polymorphism microarrays or
array comparative genomic hybridization (CGH), has allowed
genotyping of larger disease cohorts and controls. Two major
principles have emerged from these more recent studies: (i)
common copy number polymorphism predisposes certain
chromosomes to recurrent deletions and duplications and
(ii) association of the same recurrent genomic lesion with
apparently very diverse phenotypes. The latter has begun to
illuminate common neurodevelopmental pathways and
helps to explain the comorbidity of diverse neurological
manifestations within the same families. The distinction
between variability of expressivity and reduced penetrance
depending on the diagnosis has become an important consider-
ation for these rare mutational events. We will explore the
mechanisms, models and implications underlying these two
different aspects.
GENOMIC SUSCEPTIBILITY TO RECURRENT
DELETIONS AND DUPLICATIONS
Seminal work on Charcot–Marie–Tooth disease (1,2) and
hereditary neuropathy with liability to pressure palsies
(HNPP) (3) directly implicated low-copy repeats or segmental
duplications as substrates for unequal crossover or non-allelic
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“Rare	  CNVs	  wer 	   bserve 	  in	  regions	  w th	   trong	  previ u ly	  documented	  associaRon	  
with	  schizophrenia,	  but	  with	  va iable	  paQern 	  of	  segregaRon.	  This	  should	  serve	  as	  a	  
reminder	  that	  we	  sRll	  know	  relaRvely	  liQle	  about	  the	  distribuRon	  of	  these	  CNVs	  in	  the	  
enRre	  populaRon	  (e.g.,	  in	  individuals	  with	  no	  or	  only	  mild	  cog iRve	  problems)	  or	  
about	  the	  reasons	  for	  the	   mergence	  of	  schizophrenia	  in	  only	  a	  minority	  of	   rriers,	  so	  
great	  cauRon	  is	  required	  in	  geneRc	  counseling	  and	  prediagnosis.”	  	  
	  
Clinical	  Management	  and	  GeneRcs	  
Genet	  Med.	  2011	  Sep;13(9):770-­‐6.	  
	  
Chromosomal	  microarray	  tes*ng	  inﬂuences	  medical	  management.	  
Coulter	  ME,	  Miller	  DT,	  Harris	  DJ,	  Hawley	  P,	  Picker	  J,	  Roberts	  AE,	  Sobeih	  MM,	  Irons	  M.	  
	  
PURPOSE:	  	  
Chromosomal	  microarray	  (CMA)	  tesRng	  provides	  the	  highest	  diagnosRc	  yield	  for	  clinical	  tesRng	  of	  paRents	  with	  
developmental	  delay	  (DD),	  intellectual	  disability	  (ID),	  mulRple	  congenital	  anomalies	  (MCA),	  and	  auRsm	  spectrum	  
disorders	  (ASD).	  Despite	  improved	  diagnosRc	  yield	  and	  studies	  to	  support	  cost-­‐eﬀecRveness,	  concerns	  regarding	  the	  
cost	  and	  reimbursement	  for	  CMA	  have	  been	  raised	  because	  it	  is	  perceived	  that	  CMA	  results	  do	  not	  inﬂuence	  medical	  
management.	  
METHODS:	  	  
We	  conducted	  a	  retrospecRve	  chart	  review	  of	  CMA	  tesRng	  performed	  during	  a	  12-­‐month	  period	  on	  paRents	  with	  DD/
ID,	  ASD,	  and	  congenital	  anomalies	  to	  determine	  the	  proporRon	  of	  cases	  where	  abnormal	  CMA	  results	  impacted	  
recommendaRons	  for	  clinical	  acRon.	  
RESULTS:	  	  
Among	  1792	  paRents,	  13.1%	  had	  clinically	  relevant	  results,	  either	  abnormal	  (n	  =	  131;	  7.3%)	  or	  variants	  of	  possible	  
signiﬁcance	  (VPS;	  n	  =	  104;	  5.8%).	  Abnormal	  variants	  generated	  a	  higher	  rate	  of	  recommendaRon	  for	  clinical	  acRon	  
(54%)	  compared	  with	  VPS	  (34%;	  Fisher	  exact	  test,	  P	  =	  0.01).	  CMA	  results	  inﬂuenced	  medical	  care	  by	  precipitaRng	  
medical	  referrals,	  diagnosRc	  imaging,	  or	  speciﬁc	  laboratory	  tesRng.	  
CONCLUSIONS:	  	  
For	  all	  test	  indicaRons,	  CMA	  results	  inﬂuenced	  medical	  management	  in	  a	  majority	  of	  paRents	  with	  abnormal	  variants	  
and	  a	  substanRal	  proporRon	  of	  those	  with	  VPS.	  These	  results	  support	  the	  use	  of	  CMA	  as	  a	  clinical	  diagnosRc	  test	  that	  
inﬂuences	  medical	  management	  for	  this	  paRent	  populaRon.	  
